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Abstract 23 
Both plasma and cerebrospinal fluid (CSF) are rich in cholesterol and its metabolites. Here we describe 24 
in detail a methodology for the identification and quantification of multiple sterols including 25 
oxysterols and sterol-acids found in these fluids. The method is translatable to any laboratory with 26 
access to liquid chromatography – tandem mass spectrometry. The method exploits isotope-dilution 27 
mass spectrometry for absolute quantification of target metabolites. The method is applicable for 28 
semi-quantification of other sterols for which isotope labelled surrogates are not available and 29 
approximate quantification of partially identified sterols. Values are reported for non-esterified sterols 30 
in the absence of saponification and total sterols following saponification. In this way absolute 31 
quantification data is reported for 17 sterols in the NIST SRM 1950 plasma along with semi-32 
quantitative data for 8 additional sterols and approximate quantification for one further sterol. In a 33 
pooled (CSF) sample used for internal quality control, absolute quantification was performed on 10 34 
sterols, semi-quantification on 9 sterols and approximate quantification on a further three partially 35 
identified sterols. The value of the method is illustrated by confirming the sterol phenotype of a 36 
patient suffering from ACOX2 deficiency, a rare disorder of bile acid biosynthesis, and in a plasma 37 
sample from a patient suffering from cerebrotendinous xanthomatosis, where cholesterol 27-38 
hydroxylase is deficient.       39 
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1. Introduction  40 
Plasma/serum and cerebrospinal fluid (CSF) represent body fluids widely studied with an ultimate goal 41 
of revealing biomarkers of disease [1-7]. Plasma/serum analysis by mass spectrometry (MS) can prove 42 
particularly fruitful to reveal inborn errors of metabolism, especially those related to cholesterol 43 
biosynthesis and metabolism [8-12], while analysis of CSF may have value to monitor 44 
neurodegeneration [7, 13-15]. However, comparing data across different laboratories can prove 45 
treacherous as a consequence of multiple different platforms and methods used, and differences in 46 
the use of standards for quantification [4, 16, 17].    47 
Isotope-dilution (ID)-MS represents the most reliable methodology for the quantitative measurement 48 
of lipids, including sterols, in biological samples [18, 19]. Despite this, large differences in inter-49 
laboratory measurements may still occur even when using ID-MS [16, 17]. These differences, should, 50 
however, be minimised by the use of common isotope-labelled standards accurately prepared in a 51 
suitable solvent for distribution to laboratories world-wide. In the era of “omic” science, there is a 52 
drive for the quantification of multiple analytes in a single sample and this has led to the development 53 
of commercial mixtures of accurately aliquoted combinations of different isotope-labelled standards 54 
to allow the quantification of multiple lipids in a single analysis [1, 20]. At the more targeted level, a 55 
commercial kit containing a mixture of twenty different isotope-labelled bile acids is now available 56 
[21]. A second challenge for the inter-laboratory comparison of quantitative data is provided by the 57 
variation in the exact nature of the samples analysed and compared. This problem can be overcome 58 
by the use of well documented Standard Reference Materials (SRMs).  59 
Here, we report the absolute quantification of 17 sterols, including oxysterols and cholestenoic acids 60 
in an SRM plasma sample (NIST SRM 1950 [22, 23]) using isotope-labelled cholesterol and a recently 61 
commercialised mixture of other isotope-labelled sterols. We have quantified the oxysterols as non-62 
esterified free molecules and, where possible, following saponification of esters. In addition, the 63 
mixture of isotope-labelled standards has been used to for the semi-quantification of 8 other sterols 64 
including oxysterols and sterol-acids in plasma where authentic, but not isotope-labelled standards, 65 
were available. Approximate quantification of one further sterol was made in the absence of an 66 
available authentic standard. Seven other sterols were identified but not quantified, while 8 further 67 
sterols were partially identified in the absence of authentic standards and were not quantified. Note, 68 
here we explicitly use the terms: absolute quantification to define quantification performed against 69 
an isotope-labelled surrogate of otherwise exactly the same structure, e.g. (25R)26-70 
hydroxycholesterol [(25R)26-HC] against [25,26,26,27,27,27-2H6](25R)26-HC; semi-quantification to 71 
define quantification against an isotope labelled surrogate of similar but not identical structure, e.g. 72 
3β,7β-dihydroxycholest-5-en-26-oic acid (3β,7β-diHC) against [27,27,27-2H3]3β,7α-dihydroxycholest-73 
5-en-26-oic acid ([2H3]3β,7α-diHCA); and approximate quantification to define quantification against 74 
an isotope labelled surrogate, but in the absence of an authentic standard of the sterol to be quantified 75 
i.e. 7α-hydroxy-27-norcholest-4-ene-3,24-dione (7αH,27-nor-C-3,24-diO) against [2H6](25R)26-HC. 76 
The equivalent numbers of quantified/identified sterols in an internal quality control (QC) CSF sample 77 
were: absolute quantification of 10 sterols, semi-quantification of 9 sterols and approximate 78 
quantification of 3 sterols. In addition, 5 other sterols were presumptively identified in the absence of 79 
authentic standards but not quantified. It should be noted, that besides the sterols reported here in 80 
the SRM plasma and QC CSF, a very large number of additional oxysterols and sterol-acids have been 81 
detected in samples from patients suffering from inborn errors of sterol metabolism, which are 82 
quantitatively minor in samples from healthy individuals [24-28]. We demonstrate the value of the 83 
analytical method employed by confirming the sterol phenotype of two such inborn errors of 84 
metabolism i.e. ACOX2 (acyl-CoA oxidase 2) deficiency and cerebrotendinous xanthomatosis (CTX), 85 
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two rare disorder of bile acid biosynthesis [10, 29-31]. These disorders highlight the value of the 86 
methodology to discriminate between diastereomers with asymmetric carbons at C-24 e.g. 24S-87 
hydroxycholesterol (24S-HC) and 24R-HC, and at C-25 e.g. 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic 88 
acid [7αH,3O-CA(25R)] and 7αH,3O-CA(25S). Note, Supplemental Table S1 provides a list of systematic 89 
names, common names and abbreviations.          90 
2. Experimental 91 
2.1. Materials   92 
OxysterolSPLASHTM, a recently commercialised mixture of oxysterols and cholestenoic acids was 93 
provided by Avanti Polar Lipids Inc (AL, USA). The mixture consists of the following isotope-labelled 94 
standards in methanol solvent; [25,26,26,26,27,27,27-2H7]24R/S-HC ([2H7]24R/S-HC, 80 ng/mL), 95 
[26,26,26,27,27,27-2H6]25-hydroxycholesterol ([2H6]25-HC, 10 ng/mL), [25,26,26,27,27,27-96 
2H6](25R)26-HC ([2H6](25R)26-HC, also called [2H6]27-hydroxycholesterol, 160 ng/mL, note 97 
[2H5](25R)26-HC is also present at a level of about 15% of that of the [2H6]-isotopolouge), 98 
[25,26,26,26,27,27,27-2H7]7α-hydroxycholesterol ([2H7]7α-HC, 60 ng/mL), [25,26,26,26,27,27,27-99 
2H7]7β-hydroxycholesterol ([2H7]7β-HC, 10 ng/mL), [25,26,26,26,27,27,27-2H7]7-oxocholesterol 100 
([2H7]7-OC, 30 ng/mL), [25,26,26,26,27,27,27-2H7]7α-hydroxycholest-4-en-3-one ([2H7]7α-HCO, 20 101 
ng/mL), [26,26,26,27,27,27-2H6]7α,25-dihydroxycholesterol ([2H6]7α,25-diHC, 1 ng/mL), 102 
[25,26,26,27,27,27-2H6]7α,(25R/S)26-dihydroxycholesterol ([2H6]7α,(25R/S)26-diHC, also called 103 
[2H6]7α,27-dihydroxycholesterol, 2 ng/mL), [27,27,27-2H3]7αH,3O-CA(25R/S) ([2H3]7αH,3O-CA(25R/S), 104 
70 ng/mL), [25,26,26,26,27,27,27-2H7]4β-hydroxycholesterol ([2H7]4β-HC, 30 ng/mL), 105 
[25,26,26,26,27,27,27-2H7]22R-hydroxycholesterol ([2H7]22R-HC, 5 ng/mL) and [25,26,26,26,27,27,27-106 
2H7]cholestane-3β,5α,6β-triol ([2H7]5α,6β-diHC, 10 ng/mL). Additional quantitative isotope labelled 107 
standards provided in methanol in exact quantities from Avanti Polar Lipids were [26,26,26,27,27,27-108 
2H6]24R/S-HC (51.95 µg/mL, LM-4110), [2H7]7α-HC (48.74 μg/mL, LM-4103), [2H7]7-OC (51.42 μg/mL, 109 
LM-4107) and [25,26,26,26,27,27,27-2H7]cholesterol (526.01 µg/mL, LM-4100). The isotope labelled 110 
standards listed above were provided at defined concentrations by Avanti Polar Lipids and were used 111 
without further purification or validation. Certificate of analysis for OxysterolSPLASH and the other 112 
quantitative isotope labelled standards are available at https://avantilipids.com/. Other isotope-113 
labelled standards, [25,26,26,26,27,27,27-2H7]22S-hydroxycholesterol ([2H7]22S-HC), [2H7]5α,6β-diHC 114 
and [2H6]7α,25-diHC and were also from Avanti Polar Lipids Inc. Additional non-labelled standards 115 
were from Avanti Polar Lipids or as indicated in Table S1. Sterols with a 3-oxo-4-ene structure were 116 
generated from 3β-hydroxy-5-ene analogues by treatment with cholesterol oxidase [26]. Cholesterol 117 
oxidase from Streptomyces sp. and [2H0]Girard P ([2H0]GP, chloride salt) were from Merck, Dorset, UK 118 
and TCI Europe, respectively. [2H5]GP (bromide salt) was synthesised as described by Crick et al [26]. 119 
Pooled human plasma was NIST SRM 1950, Gaithersburg, MD, USA [22]. Pooled CSF was QC material 120 
generated by combining individual CSF samples from multiple donors in a study performed in 121 
association with the NYPUM project at the University Hospital of Umeå, Sweden. Plasma from a 122 
patient suffering from ACOX2 deficiency was as described in [10]. Plasma from a CTX patient was from 123 
previous studies in our laboratories. All participants or their parents/guardians provided informed 124 
consent and the studies were performed with institutional review board approval and adhered to the 125 
principles of the Declaration of Helsinki.  126 
2.2. Extraction of non-esterified sterols including oxysterols and sterol-acids 127 
2.2.1. Plasma - OxysterolSPLASH  128 
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Plasma (100 µL) was added dropwise to an alcohol solution (1.050 mL) made up of 50 µL of 129 
OxysterolSPLASH ([2H7]24R/S-HC, 4 ng; [2H6]25-HC, 0.5 ng; [2H6](25R)26-HC, 8 ng; [2H7]7α-HC, 3 ng; 130 
[2H7]7β-HC, 0.5 ng; [2H7]7-OC, 1.5 ng; [2H7]7α-HCO, 1 ng; [2H6]7α,25-diHC, 0.05 ng; [2H6]7α,(25R/S)26-131 
diHC, 0.1 ng; [2H3]7αH,3O-CA(25R/S), 3.5 ng; [2H7]4β-HC, 1.5 ng; [2H7]22R-HC, 0.25 ng; and 5α,6β-diHC, 132 
0.5 ng) and 1.000 mL of ethanol containing [25,26,26,26,27,27,27-2H7]22S-hydroxycholest-4-en-3-one 133 
([2H7]22S-HCO, 10 ng) and [2H7]cholesterol (20 µg) in a microcentrifuge tube under sonication in an 134 
ultrasonic bath. The solution was diluted with 350 µL water to give a 70% alcohol solution (1.500 mL). 135 
This was sonicated for a further 5 min, then centrifuged at 17,000 x g at 4 oC for 30 min (see 136 
Supplemental Methods for flowchart 1). 137 
For standard addition experiments unlabelled authentic standards (5 quantities covering a 5-fold 138 
concentration range, see Supplemental Table S3A) were added in differing quantities to 100 µL of 139 
plasma with the protocol otherwise unchanged. For experiments to optimise the quantity of 140 
OxysterolSPLASH the original protocol was followed with 100 µL plasma added to 1.050 mL of alcohol 141 
containing different amounts of OxysterolSPLASH (100 µL, 50µL, 25 µL, 12.5 µL or 6.25 µL, see 142 
Supplemental Table S2 and Supplemental Methods for flowchart 2).     143 
Oxysterols and sterol-acids were separated from cholesterol and sterols of similar lipophilicity by solid 144 
phase extraction (SPE), using a “certified Sep-Pak tC18” column (200 mg, Waters Inc, Elstree, Herts, 145 
UK). The column, SPE1, was first washed with absolute ethanol (4 mL), then conditioned with 70% 146 
ethanol (6 mL). The sterol extract from above in 70% alcohol (1.5 mL) was applied to the column and 147 
allowed to flow at a rate of 0.25 mL/min. If necessary, flow was assisted by negative pressure at the 148 
column outlet. The column flow-through was collected and combined with a column wash of 70% 149 
ethanol (5.5 mL). Oxysterols and sterol-acids elute in this fraction SPE1-Fr1 (7 mL, 70% alcohol). The 150 
column was washed further with 70% ethanol (4 mL) to give SPE1-Fr2. Cholesterol and sterols of 151 
similar lipophilicity were eluted with absolute ethanol (2 mL) to give SPE1-Fr3. More lipophilic sterols 152 
were eluted with further absolute ethanol (2 mL) to give SPE1-Fr4. Each fraction was divided into two 153 
equal parts (A) and (B) and lyophilised. 154 
2.2.2. Plasma - Quantitative isotope-labelled standards 155 
Plasma (100 µL) was added dropwise to absolute ethanol (1.050 mL) containing quantitative isotope-156 
labelled internal standards [2H6]24R/S-HC (20 ng), [2H7]7α-HC (20 ng), [2H7]7-OC (20 ng) and 157 
[2H7]cholesterol (20 µg) along with standards [25,26,26,26,27,27,27-2H7]22R-hydroxycholest-4-en-3-158 
one ([2H7]22R-HCO, 20 ng) or [2H7]22S-HCO (20 ng), [2H6]7α,25-diHC (2 ng) and [2H7]5α,6β-diHC (20 ng) 159 
in a microcentrifuge tube under sonication in an ultrasonic bath. The solution was diluted with 350 µL 160 
of water to give a 70% alcohol solution. This was sonicated for a further 5 min, then centrifuged at 161 
17,000 x g at 4oC for 30 min. Further sample preparation was exactly as in 2.2.1. 162 
2.2.3. CSF - OxysterolSPLASH 163 
CSF (100 µL) was added drop-wise to an alcohol solution (2.100 mL) made up of 20 µL OxysterolSPLASH 164 
(containing [2H7]24R/S-HC, 1.6 ng; [2H6]25-HC, 0.2 ng; [2H6](25R)26-HC, 3.2 ng; [2H7]7α-HC, 1.2 ng; 165 
[2H7]7β-HC, 0.2 ng; [2H7]7-OC, 0.6 ng; [2H7]7α-HCO, 0.4 ng; [2H6]7α,25-diHC, 0.02 ng; [2H6]7α,(25R/S)26-166 
diHC, 0.04 ng; [2H3]7αH,3O-CA(25R/S), 1.4 ng; [2H7]4β-HC, 0.6 ng; [2H7]22R-HC, 0.1 ng; and [2H7]5α,6β-167 
diHC, 0.2 ng), 10 µL methanol (containing [2H7]22S-HCO (1 ng) and [2H7]cholesterol (200 ng) and 2.070 168 
mL of absolute ethanol in a 15 mL Corning tube under sonication in an ultrasonic bath. The solution 169 
was diluted to 70% ethanol by the addition of water (800 µL), sonicated for 5 min, then centrifuged at 170 
2,400 x g at 4°C for 30 minutes. Alternatively, the CSF volume was either 200 µL, 100 µL or 50 µL and 171 
the OxysterolSPLASH volume varied between 10 µL and 20 µL, maintaining overall alcohol and 172 
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aqueous volumes as above. For standard addition experiments unlabelled authentic standards were 173 
added in differing quantities (5 quantities covering a 5-fold range, see Supplemental Table S3B) to 100 174 
µL of CSF, with the protocol using 20 µL of OxysterolSPLASH otherwise unchanged (see Supplemental 175 
Methods for flowchart 2, lower panel).   176 
Oxysterols and sterol-acids were separated from cholesterol and sterols of similar lipophilicity by SPE, 177 
using a “certified Sep-Pak tC18” column washed and conditioned as in 2.2.1. The sterol extract from 178 
CSF now in 70% alcohol (3 mL) was applied to the column and allowed to flow at a rate of 0.25 mL/min. 179 
If necessary, flow was assisted by negative pressure at the column outlet. The flow-through was 180 
collected and combined with a column wash of 70% ethanol (4 mL). Oxysterols and sterol-acids elute 181 
in this fraction SPE1-Fr1 (7 mL, 70% alcohol). The column was washed further with 70% ethanol (4 mL) 182 
to give SPE1-Fr2. Cholesterol and sterols of similar lipophilicity were eluted with absolute ethanol (2 183 
mL) to give SPE1-Fr3. More lipophilic sterols were eluted with an additional 2 mL of absolute ethanol 184 
to give SPE1-Fr4. Each fraction was divided into two equal parts A and B and lyophilised. 185 
2.2.4. CSF - Quantitative isotope-labelled standards 186 
The procedure described in 2.2.3 was repeated, except 250 µL of CSF was added to an ethanol solution 187 
(2.100 mL) containing [2H7]24R/S-HC (2 ng), [2H7]7α-HC (2 ng), [2H7]22R-HCO (2 ng) and 188 
[2H7]cholesterol (800 ng) prior to dilution to 3 mL of 70% ethanol.       189 
2.3. Extraction and hydrolysis of esterified sterols including oxysterols and sterol-acids 190 
2.3.1. Plasma - OxysterolSPLASH   191 
Plasma (100 µL) was added drop-wise to a freshly prepared solution of 0.35 M KOH [19] in 1.050 mL 192 
of alcohol made up of OxysterolSPLASH (50 µL), [2H7]22S-HCO (10 ng) and [2H7]cholesterol (40 µg) in 193 
methanol (100 µL) and ethanolic KOH (900 µL, 3.66 x 10-4 mole KOH), under sonication in a 194 
microcentrifuge tube. The solution was sonicated for a further 5 min and incubated at room 195 
temperature in the dark for 2 hr, after which it was neutralised by addition of 350 µL of water 196 
containing 21 µL of glacial acetic acid (3.66 x 10-4 mole). The mixture was then ultrasonicated for 5 min 197 
and then centrifuged at 17,000 x g at 4 oC to remove any precipitated matter. The solution (1.5 mL, 198 
70% alcohol) was then applied to SPE1 and processed as in 2.2.1. 199 
The procedure was repeated with the same volume of plasma (100 µL) but the volume of 200 
OxysterolSPLASH was varied from 200 µL to 6.25 µL. To maintain the ultimate volume of alcohol at 201 
1.050 mL at 0.35 M KOH the volume and molarity of ethanolic KOH was adjusted appropriately. An 202 
additional experiment was performed with a plasma volume of 10 µL, volume of OxysterolSPLASH of 203 
10 µL and keeping the aqueous and alcohol proportions unchanged but reducing [2H7]cholesterol 204 
proportionately to the reduction in OxysterolSPLASH. 205 
2.3.2. CSF - OxysterolSPLASH 206 
CSF (100 µL) was added dropwise to a freshly prepared solution made up of OxysterolSPLASH (20 µL), 207 
[2H7]22S-HCO (1 ng) and [2H7]cholesterol (200 ng) in methanol (10 µL) and 2.070 mL of 0.35 M 208 
ethanolic KOH (7.25 x 10-4 mole) under sonication. The solution was sonicated for a further 5 min and 209 
incubated at room temperature in the dark for 2 hr, after which it was neutralised by addition of 800 210 
µL of water containing 41.6 of µL glacial acetic acid (7.25 x 10-4 mole). The mixture was then 211 
ultrasonicated for 5 min and then centrifuged at 2,400 x g at 4oC to remove any precipitated matter. 212 
The solution (3 mL, 70% alcohol) was then applied to SPE1 and processed as in 2.2.3. The procedure 213 
was repeated with the CSF volume increased to 200 µL and the volume of water adjusted to give a 214 
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final volume of 3 mL, 70% alcohol. In a further experiment, OxysterolSPLASH was replaced by 215 
[2H6]24R/S-HC (2 ng) in ethanol.    216 
2.4. Enzyme-assisted derivatisation for sterol analysis (EADSA) 217 
To enhance the signal for sterol, oxysterol and sterol-acid analysis by liquid chromatography (LC)-MS 218 
derivatisation strategies are often used [32-35]. Here to enhance the signal in LC - electrospray 219 
ionisation (ESI)-MS we have adopted EADSA technology described in Figure 1 [26, 31]. 220 
Each dried SPE1 fraction was reconstituted in propan-2-ol (100 µL) and thoroughly vortexed. To A-221 
fractions 50 mM phosphate buffer (KH2PO4, pH 7, 1.000 mL) containing cholesterol oxidase (3 µL, 2 222 
µg/µL in water, 44 mU/µg protein) was added and the mixture incubated at 37 oC for 1 hr, after which 223 
the reaction was quenched with methanol (2.000 mL). Glacial acetic acid (150 µL) was then added and 224 
the solution thoroughly vortexed. [2H5]GP reagent (190 mg, bromide salt) was added to this solution 225 
which was thoroughly vortexed and incubated at room temperature overnight in the dark. B-fractions 226 
were treated in an identical manner but in the absence of cholesterol oxidase and with [2H0]GP (150 227 
mg, chloride salt) replacing [2H5]GP. When a hydrolysis step was included, for plasma analysis the 228 
above mixture was centrifuged at 2,400 x g at room temperature for 30 minutes prior to further 229 
sample preparation. This was performed to avoid blocking of the second SPE column (see below).  230 
To remove excess derivatisation reagent the reaction mixture was subjected to a second SPE step, i.e. 231 
SPE2. An Oasis HLB column (60 mg, Waters Inc) was washed with 100% methanol (6 mL), 10% 232 
methanol (6 mL) and conditioned with 70% methanol (4 mL). The reaction mixture from above (3.25 233 
mL, 69% organic) was loaded onto the column followed by 70% methanol (1 mL), used to rinse the 234 
reaction vial. The combined eluent was diluted with water (4 mL) to 35% methanol. The column was 235 
equilibrated with 35% methanol (1 mL) which was added to the diluted eluent to give 9 mL of 35% 236 
methanol. This solution was re-applied to the column and the eluent diluted with water (9 mL) to give 237 
18 mL of 17.5% methanol. The column was equilibrated with 17.5% methanol (1 mL) and eluents 238 
combined. The resultant solution (19 mL 17.5% methanol) was applied to the column and the effluent 239 
discarded. At this point all GP-derivatised sterols including oxysterols and sterol-acids are retained on 240 
the column. The column was finally washed with 10% methanol (6 mL) and GP-derivatives eluted in 3 241 
x 1 mL of methanol followed by 1 mL of ethanol. Oxysterols and cholestenoic acids elute in the first 242 
two 1 mL fractions (SPE2-Fr1+Fr2), and cholesterol elutes across the first three 1 mL fractions (SPE2-243 
Fr1+Fr2+Fr3). For oxysterol and sterol-acid analysis equal volumes of SPE2-Fr1+Fr2 derived from 244 
fraction-A and from fraction-B were then combined diluted to 60% methanol and analysed by LC-MS. 245 
Similarly, for cholesterol analysis, equal volumes of SPE2-Fr1+Fr2+Fr3 derived originally from SPE1-246 
Fr3A and from SPE1-Fr3B were combined and diluted to 60% methanol, followed by dilution by a 247 
factor of up to 1000 in 60% methanol and analysed by LC-MS. Note, in 100% methanol the derivatives 248 
are stable for several months when stored at -20 oC [26, 31]. 249 
2.5. LC-MS with multistage fragmentation (MSn)  250 
Analysis was performed on either an Orbitrap Elite mass spectrometer equipped with an ESI probe 251 
(Thermo Fisher Scientific, Hemel Hempstead, UK) with prior chromatographic separations on an 252 
Ultimate 3000 LC system (Dionex, now Thermo Fisher Scientific), essentially as described previously 253 
[28, 31] or on an Orbitrap IDX Tribrid mass spectrometer similarly equipped with an ESI probe and 254 
linked to an Ultimate 3000 LC system. The column used was Hypersil Gold C18 (50 x 2.1 mm, 1.9 µm, 255 
Thermo Fisher Scientific). Two chromatographic gradients were employed, a 17 min gradient and a 35 256 
min gradient described in [28, 31]. On the Orbitrap Elite instrument three to five scan events were 257 
performed: one high resolution (120,000, FWHM at m/z 400) MS scan event in the Orbitrap analyser 258 
7 
 
in parallel with two to four multi-stage fragmentation (MSn) scan events in the linear ion trap (LIT). 259 
Similar scan parameters were utilised on the IDX instrument. One scan event was performed in the 260 
Orbitrap analyser (120,000 FWHM at m/z 400) in parallel to five scan events in the ion trap. One 261 
difference between MSn scans on the Orbitrap Elite and IDX is that with the Elite all m/z selection is in 262 
the LIT, while on the IDX the first m/z selection was by the quadropole mass filter. Quantification was 263 
performed by stable isotope dilution or using isotope labelled structurally similar compounds. 264 
3. Results 265 
3.1. Non-esterified sterols including oxysterols and sterol-acids in plasma 266 
3.1.1. Chromatography of GP-derivatised sterols including oxysterols and cholestenoic acids targeted 267 
by OxysterolSPLASH 268 
Most of the GP-derivatised monohydroxycholesterols (HC) targeted by the OxysterolSPLASH mix are 269 
chromatographically separated by the 17 min and 37 min gradients (Figure 2). In fact, the high 270 
selectivity of the chromatographic system employed results in chromatographic separation of GP-271 
derivatised epimeric oxysterols e.g. 24S-HC and 24R-HC (asymmetric carbon at C-24, see Figure 2A, 272 
lower panel), which is not normally achieved in conventional LC-MS or gas chromatography (GC)-MS 273 
studies [36, 37]. This is advantageous as it allows the detection of both the major (24S-HC) and minor 274 
(24R-HC) epimers of 24-HC in human plasma. However, this advantage comes with the penalty of 275 
complicating the ultimate chromatogram. The chromatographic system employed also has the 276 
selectivity to separate syn and anti conformers of the GP-derivative (see Supplemental Figure S1), 277 
thereby enhancing the reliability of identification of oxysterols but further complicating the 278 
chromatogram and consequently 24S-HC and 24R-HC each give two chromatographic peaks (Figure 279 
2A, lower panel). 280 
Of the monohydroxycholesterols targeted by the OxysterolSPLASH mix 24R-HC is only partially 281 
resolved in time from (25R)26-HC (Figure 2A). This does not create a problem for human plasma or 282 
CSF samples as 24R-HC is only a minor component of both fluids (i.e. <10% of 24S-HC and <5% of 283 
(25R)26-HC) and there is minimal distortion of the peak shape for (25R)26-HC in the appropriate 284 
reconstructed ion chromatogram (RIC, m/z 539.4368 ± 5 ppm, Figure 2A). [2H7]24-HC in the 285 
OxysterolSPLASH mix is a mixture of [2H7]24R-HC and [2H7]24S-HC and the certified concentration is 286 
for the combination of the two i.e. 80 ng/mL (Figure 2B, lower panel). Assuming an identical response 287 
factor for the two epimers the concentration of the [2H7]24S-HC epimer in the OxysterolSPLASH mix 288 
was determined to be 35.44 ng/mL and can thus be used for quantification of endogenous 24S-HC. 289 
The partial chromatographic resolution (in time) of [2H7]24R-HC and [2H6](25R)26-HC in the 290 
OxysterolSPLASH mix does not affect the chromatographic peak for [2H6](25R)26-HC (Figure 2C) as 291 
[2H6](25R)26-HC (m/zcalc 545.4744) is 1 Da lighter than [2H7]24R-HC (m/zcalc 546.4807) and they are 292 
resolved by mass. However, the M+1 peak of [2H6](25R)26-HC (m/zcalc 546.4777) has almost the same 293 
mass as [2H7]24R-HC and the two isomers are not resolved by mass (Supplemental Figure S2A). This 294 
distorts the RIC peak of [2H7]24R-HC as indicated by the green arrow in Figure 2B (upper panel). 295 
However, if 24R-HC is of interest in biological samples, this problem is readily overcome by generating 296 
multiple-reaction-monitoring (MRM) chromatograms utilising the LIT for fragmentation of 24R/S-HC 297 
and [2H7]24R/S-HC and exploiting the transitions [M]+→[M-Py]+→353.3, where Py corresponds to 298 
pyridine (Figure 2A & 2B, lower panels). As the fragment ion at m/z 353.3 is a major ion in the MS3 299 
spectra of 24R-HC and 24S-HC (Supplemental Figure S3A – S3D, see also Figure S4A for mechanism of 300 
formation) but is essentially absent (RA <1%) from the fragmentation spectrum of (25R)26-HC 301 
(Supplemental; Figure S3G & S3H), (25R)26-HC is essentially transparent to this transition. Besides 302 
24S-HC, 24R-HC and (25R)26-HC, other targeted monohydroxycholesterols, 25-HC, 7α-HC and 7β-HC 303 
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are separated as is evident in Figures 2A (upper panel) and also by the shorter gradient as shown in 304 
Figure 2D (upper panel). 22R-HC is a minor oxysterol in adult plasma and is not detected in the NIST 305 
SRM 1950 plasma sample (Figure 2A & 2D, upper panels), although the isotope labelled form is clearly 306 
evident (Figures 2B upper panel & 2D lower panel). It is noteworthy that 22R-HC is evident in plasma 307 
from pregnant women. While GP-derivatised monohydroxycholesterols are exclusive to the A-308 
fractions and have an odd numbered mass, the hydroxycholestenones (HCO), 7α-HCO and 7-OC 309 
appear in B-fractions and have an even numbered mass (Figure 2E & Supplemental Figure S2B, see 310 
Figure S5 for MS3 spectra). Note, during GP-derivatisation 5α,6β-diHC becomes dehydrated to 6β-311 
hydroxycholesterol and this is the species monitored here (6β-HC, i.e. 5α,6β-diHC-18).   312 
Isotope-labelled dihydroxycholesterols (diHC) in the OxysterolSPLASH mix include [2H6]7α,25-diHC and 313 
a mixture of [2H6]7α,(25R)26-diHC and [2H6]7α,(25S)26-diHC epimers (asymmetric carbon at C-25). 314 
Following GP-derivatisation all three isomer are resolved almost to base line in the 17 min gradient 315 
(Figure 3A & 3B, lower panels) and to base line in the 37 min gradient (Supplemental Figure S6A, lower 316 
panel). A similar response factor is assumed for [2H6]7α,(25R)26-diHC and [2H6]7α,(25S)26-diHC and 317 
we have measured the quantity of the 7α,(25R)26-diHC and 7α,(25S)26-diHC epimers in combination 318 
in the plasma sample. If the individual epimers are of interest, their quantities could be measured. In 319 
human plasma the dihydroxycholestenones (diHCO) 7α,(25R/S)26-dihydroxycholest-4-en-3-one 320 
(7α,(25R/S)26-diHCO) and 7α,25-dihydroxycholest-4-en-3-one (7α,25-diHCO) are more abundant 321 
than the analogous dihydroxycholesterols (Table 1, Figure 3C). The dihydroxycholesterol isomers are 322 
only found in fraction-A while the dihydroxycholestenone isomers are in both A- and B-fractions. The 323 
amount of dihydroxycholestenone is that measured in fraction-B and that of dihydroxycholesterol 324 
calculated by subtracting values in fraction-B from those in fraction-A. MS3 spectra of 325 
dihydroxycholesterols and dihydroxycholestenones are presented in Supplemental Figure S7. 326 
In human plasma the cholestenoic acid 7αH,3O-CA(25R/S) is abundant, predominantly as the 25R-327 
epimer (asymmetric carbon at C-25), although the 25S-epimer is also present to a lesser extent (Figure 328 
3D). In both the 17 min and 37 min (see Supplemental Figure S6C) gradients the two epimers are 329 
almost completely resolved, but not quite to base line. Here we assume an equivalent response factor 330 
for both epimers and have determined their quantity in combination and also as individual epimers 331 
using the [2H3]7αH,3O-CA(25R/S) internal standard (Table 1). In addition to 7αH,3O-CA(25R/S), both 332 
epimers of 3β,7α-dihydroxycholest-5-en-(25R/S)26-oic acid [(3β,7α-diHCA(25R/S)] (Figure 3E) are 333 
observed in plasma and were quantified using [2H3]7αH,3O-CA(25R/S). Their combined concentration 334 
is reported and also for the individual epimers (Table 1).  335 
Besides the oxysterols and cholestenoic acids targeted in the OxysterolSPLASH mix, cholesterol was 336 
also quantified via an additional quantitative standard, [2H7]cholesterol. Cholesterol and similarly 337 
lipophilic sterols, 8(9)-dehydrocholesterol (8-DHC), an enzymatically formed isomer of 7-338 
dehydrocholesterol (7-DHC) [38], and desmosterol are separated from oxysterols and sterol-acids on 339 
SPE1 during sample preparation and analysed in a separate LC-MS(MSn) run (Supplemental Figure S9). 340 
3.1.2. Chromatography of additional GP-derivatised sterols including oxysterols and sterol-acids 341 
Besides the oxysterols and cholestenoic acids targeted for absolute quantification by the 342 
OxysterolSPLASH mix there are numerous other sterols and cholesterol metabolites revealed by 343 
EADSA and LC-MS(MSn) analysis of plasma (see Supplemental Methods for flowchart 3 illustrating the 344 
identification process)  [39, 40], these include 25-hydroxyvitamin D3 (25-D3, Supplemental Figure S10), 345 
7α,12α-dihydroxycholesterol (7α,12α-diHC) and 7α,12α-dihydroxycholest-4-en-3-one (7α,12α-diHCO, 346 
Figure 3A - C); 3β-hydroxycholest-5-en-(25R)26-oic (3β-HCA) and 3-oxocholest-4-en-(25R)26-oic (3O-347 
CA) acids (Supplemental Figure S10D); both 25R and 25S epimers of 3β,7β-dihydroxycholest-5-en-348 
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(25R/S)26-oic acid ([3β,7β-diHCA(25R/S)], Figure 3E);  3β,7α,24-trihydroxycholest-5-en-26-oic acid 349 
(3β,7α,24-triHCA) in combination with 7α,24-dihydroxy-3-oxocholest-4-en-26-oic acid (7α,24-diH,3O-350 
CA, Supplemental Figure S10E & F); 3β,7α,25-trihydroxycholest-5-en-26-oic acid (3β,7α,25-triHCA) in 351 
combination with 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid (7α,25-diH,3O-CA, Supplemental 352 
Figure S10E & G); 3β-hydroxychol-5-en-24-oic acid (3βH-Δ5-BA, Supplemental Figure S10B); 3β,7α-353 
dihydroxychol-5-en-24-oic (3β,7α-diH-Δ5-BA), 7α-hydroxy-3-oxochol-4-en-24-oic  (7αH,3O-Δ4-BA) and 354 
3β,7β-dihydroxychol-5-en-24-oic (3β,7β-diH-Δ5-BA, Supplemental Figure S10C) acids. Authentic 355 
standards are available for all these metabolites allowing their definitive identification. It should be 356 
noted that if 25-D3 is to be accurately quantified initial extraction from plasma should be into 357 
acetonitrile rather than ethanol [41]. 358 
In addition to the oxysterols and sterol-acids listed above we have made partial identifications of 8 359 
other sterols based on their exact mass and MS3 spectra. The interpretation of their MS3 spectra is 360 
provided in fragmentation schemes illustrated in Supplemental Figure S4 and their structures are 361 
listed in Supplemental Table S1. Simplified rules for structure determination are provided in Table S4.  362 
Table 1. Sterols including oxysterols and sterol-acids quantified, semi-quantified or approximately 363 
quantified in human plasma.             364 
3.1.3. Quantification GP-derivatised sterols including oxysterols and cholestenoic acids targeted by 365 
OxysterolSPLASH 366 
24S-HC, 25-HC, (25R)26-HC, 7β-HC and 5α,6β-diHC do not have a natural 3-oxo analogue and their GP-367 
derivatives are only found in fraction-A (Table 1). Cholesterol oxidase is required for their GP-368 
derivatisation. 7-OC is derivatised in the absence of cholesterol oxidase, hence its quantity in plasma 369 
is determined using data from fraction-B alone. 7α-HC, 7α,25-diHC, 7α,(25R/S)26-diHC, 3β,7α-370 
diHCA(25R/S) and their analogous 3-oxo compounds may be present in plasma and following GP-371 
derivatisation both 3β-hydroxy and 3-oxo entities are found in fraction-A but only the 3-ones are 372 
present in fraction-B. Note, hydroxysteroid dehydrogenase (HSD) 3B7, the dominant enzyme that 373 
converts sterols with a 3β-hydroxy-5-ene structure to a 3-oxo-4-ene in the bile acid biosynthesis 374 
pathways requires a 7α-hydroxy group in the substrate [42].   375 
3.1.3.1. Optimal amounts, standard curves, reproducibility, apparent extraction efficiency and 376 
accuracy 377 
Each of the sterols, including oxysterols and cholestenoic acids, to be quantified is naturally present 378 
in plasma. Unfortunately, unlike the situation for exogenous compounds, for sterol analysis a true 379 
blank plasma sample does not exist and neither is it possible to prepare one [43]. As pointed out by 380 
Sjövall, as the cholesterol level in plasma is so high, if sterols were to be removed from plasma, the 381 
matrix would no longer be plasma [43]. Thus, to investigate the proportionality of response to 382 
concentration, equation (1) was tested by varying the ratio of [2H0]Sterol (un-labelled) to [2Hn]Sterol 383 
(isotope-labelled standard) using otherwise unadulterated plasma.  384 
PA[2H0]Sterol / PA[2Hn]Sterol = (Rf[2H0]Sterol / Rf[2Hn]Sterol) x (Conc. [2H0]Sterol / Conc. [2Hn]Sterol) + 385 
constant  eq.1 386 
Where PA[2H0]Sterol corresponds to peak area measure for an unlabelled-sterol present in (or added 387 
to) plasma; Conc. [2H0]Sterol corresponds to the concentration of unlabelled sterol present in (or 388 
added to) plasma and Rf[2H0]Sterol corresponds to the response factor for [2H0]Sterol in (or added to) 389 
plasma. The equivalent terms, but where [2Hn] substitutes for [2H0], correspond to peak area, 390 
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concentration and response factor of isotope-labelled sterols added to plasma in the OxysterolSPLASH 391 
mix. 392 
Varying the amount of OxysterolSPLASH. Initial experiments were performed with 100 µL of plasma 393 
and adding different amounts of OxysterolSPLASH to find an optimal amount of internal standard for 394 
quantitative analysis. The experiment was performed over five concentration levels, ranging from 395 
0.0625 units (6.25 µL) of OxysterolSPLASH to 1 unit (100 µL, i.e. the volumes of plasma and 396 
OxysterolSPLASH are equivalent). For 7α,25-diHC and 7α,(25R/S)26-diHC measured in combination 397 
with their 3-ones only data for 1 – 0.25 and 1 – 0.5 units, respectively, were included due to the low 398 
levels of [2H6]7α,25-diHC and [2H6]7α,(25R/S)26-diHC in OxysterolSPLASH. The resultant data is 399 
provided in Supplemental Table S2. Equation 1 is in the form of y = mx +c and apart from 7-OC (R2 = 400 
0.97) and 5α,6β-diHC (R2 = 0.91), all analytes tested gave an R2 > 0.99. It should be noted that 7α-HC, 401 
7β-HC, 7-OC and 5α,6β-diHC can all be formed ex vivo during sample handling as well as being present 402 
in vivo [44]. With the exception of the metabolites derived by ex vivo oxidation all other analytes gave 403 
%CVs < 20% and all metabolites gave accuracy >70%, accuracy being is defined as the agreement 404 
between actual measured concentration and that derived from eq.1. 405 
As 7α,(25R/S)26-diHC is of interest in the current study, further data analysis was confined to 406 
OxysterolSPLASH quantities of 1 and 0.5 units (100 µL and 50 µL) with 100 µL of plasma. The data set 407 
was expanded by deconvoluting endogenous 3β-hydroxy compounds from their 3-oxo analogues by 408 
simply subtracting quantities measured in fraction-B from those measured in fraction-A. This provides 409 
data sets for 7α-HC, 7α,25-diHC, 7α,(25R/S)26-diHC, 3β,7α-diHCA(25R) and 3β,7α-diHCA(25S) 410 
separately from 7α-HCO, 7α,25-diHCO, 7α,(25R/S)26-diHCO, 7αH,3O-CA(25R) and 7αH,3O-CA(25S), 411 
respectively (Table 1). The agreement in data obtained with 1 unit and 0.5 units of OxysterolSPLASH 412 
was good (>80%) except for 3β,7α-diHCA(25R), where the agreement was acceptable at 77%, and for 413 
two of the oxysterols that can also be formed by ex vivo autoxidation of cholesterol i.e. 7-OC and 414 
5α,6β-diHC (both 60%). 415 
Standard additions. To further confirm the validity of eq. 1, a standard additions approach was 416 
followed in which known amounts of unlabelled standard compounds were added, over a 5-fold 417 
range, to 100 µL of plasma prior to quantification with 50 µL (0.5 units) of OxysterolSPLASH. This 418 
confirmed the validity of eq.1, as in all cases R2>0.99 and at each concentration accuracy, as 419 
determined as the % difference between the measured concentration at each level and that 420 
determined by solving equation 1, was >90% (Supplemental Table S3A). The standard additions 421 
experiment also allowed calculation of “apparent” extraction efficiency which is given by the efficiency 422 
of extraction of the added un-labelled standard. In all cases this was >90%.  423 
It is not possible to extend the calibration line to concentrations lower than those that are present 424 
endogenously in an unadulterated matrix. Instead we have exploited technical dilutions of prepared 425 
samples to estimate a lower limit of quantification as the lowest concentration at which the measured 426 
concentration of analyte differs from the calculated concentration by less than 30% (Supplemental 427 
Table S3).      428 
Comparison of OxysterolSPLASH to individual isotope-labelled standards. The current data set for 100 429 
µL plasma and 0.5 units OxysterolSPLASH was compared to data generated using the same plasma 430 
sample but exploiting individual quantitative isotope-labelled standards [2H6]24R/S-HC, [2H7]7α-HC 431 
and [2H7]7-OC. Using [2H6]24(R/S)-HC as an internal standard for 24S-HC, 25-HC and (25R)26-HC, the 432 
agreement between the methods was good (>90%), as it was also using [2H7]7α-HC for 7α-HCO, and 433 
[2H7]7-OC for 7-OC was (90%, Table 1). The agreement for 7α-HC was poor, presumably as a 434 
consequence of its formation or that of [2H7]7α-HC by ex vivo autoxidation of cholesterol or 435 
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[2H7]cholesterol, respectively. We have previously shown that using the EADSA approach [2H6]24R/S-436 
HC can be used as a reasonable surrogate for not only side-chain mono-hydroxycholesterols but also 437 
other oxysterols [26]. This is confirmed here by the good agreement (>90%) for the quantification of 438 
7α,25-diHCO and 7α,(25R/S)26-diHCO against their [2H6]-labelled authentic standards and against 439 
[2H6]24R/S-HC, respectively. Agreements for 3β,7α-diHC(25R/S) and 7αH,3O-CA(25R/S) were only 440 
moderately good (>70%) on account of the [2H6]24R/S-HC standard not taking account of the lability 441 
of the 7-hydroxy-5-ene and 7-hydroxy-4-ene-3-one skeletons, both of which are susceptible to 442 
dehydration [43].        443 
To summarise, with 100 µL of plasma and either 1 or 0.5 units of OxysterolSPLASH reproducible data 444 
is generated for the target oxysterols and cholestenoic acids, with the exception of those that can be 445 
generated by ex vivo autoxidation of cholesterol during sample work-up.  446 
3.1.4. Semi-quantification of other oxysterol and sterol-acids in the absence of isotope-labelled 447 
standards 448 
Besides cholesterol and the 16 oxysterols and cholestenoic acids listed in Table 1, semi-quantitative 449 
values were determined for another 8 sterols, oxysterols and sterol-acids in the absence of identical 450 
isotope-labelled surrogates and approximate quantification of one other oxysterol identified 451 
presumptively based on exact mass, MS3 spectrum and retention time (Table 1). The isotope-labelled 452 
standards used for each analyte were chosen based on structural similarity and are colour coded in 453 
Table 1. 454 
A further 7 oxysterols and sterol-acids were identified but not quantified, while 8 further sterols were 455 
partially identified in the absence of authentic standards and were not quantified (see Supplemental 456 
Table S1).                     457 
3.2. Esterified oxysterols in plasma 458 
Oxysterols are found in plasma in both the non-esterified (free) and esterified forms, where a hydroxy 459 
group is esterified to a fatty acyl group in a reaction predominantly catalysed by lecithin-cholesterol 460 
acyl transferase (LCAT). The esterified form is dominant [3, 19] and most GC-MS and LC-MS studies 461 
are performed after a base-hydrolysis step and measure the sum of esterified and non-esterified 462 
oxysterols [3, 16, 45-47]. We have thus hydrolysed the NIST SRM 1950 plasma sample and investigated 463 
the use of the OxysterolSPLASH mix for sterol, including oxysterol and cholestenoic acid, 464 
quantification. 465 
3.2.1. Quantification 466 
Potassium hydroxide is a strong base and besides hydrolysis of esters can catalyse the dehydration of 467 
labile hydroxy groups in sterols e.g. 7-hydroxy-5-ene and particularly 7-hydroxy-4-en-3-one [43]. If 468 
these compounds are to be analysed, an isotope-labelled version is required to take dehydration into 469 
account.    470 
3.2.2. Optimal amounts and reproducibility 471 
Having investigated earlier the proportionality of analyte response to concentration as defined by eq. 472 
1 through standard additions, we evaluated the optimum amount of OxysterolSPLASH for use when 473 
analysing 100 µL of hydrolysed plasma. The experiment was performed over five concentration levels, 474 
ranging from 0.0625 units (6.25 µL) of OxysterolSPLASH to 1 unit (100 µL). For the targeted oxysterols 475 
24S-HC, 25-HC, (25R)26-HC, 7α-HC plus 7α-HCO, 7β-HC and 7-OC R2 > 0.99, but for 7α-HCO, 5α,6β-476 
diHC, 7α,25-diHC, 7α,(25R/S)26-diHC and 7αH,3O-CA(25R/S) sufficient signal of the isotope-labelled 477 
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standard could only be achieved with 1 unit and 0.5 units of OxysterolSPLASH (data not shown). As 478 
these latter analytes are of interest, further data analysis was restricted to experiments with 100 µL 479 
of plasma and 1 or 0.5 units of OxysterolSPLASH. The agreement in analyte concentrations at these 480 
two levels of standard was >80% in all cases, except for 5α,6β-diHC (66%), which can be formed by ex 481 
vivo autoxidation of cholesterol during sample handling (Table 1). 482 
In summary, 100 µL of plasma with either 1 or 0.5 units of OxysterolSPLASH generates reproducible 483 
data for the target oxysterols and cholestenoic acids. 484 
3.2.3. Semi-quantification of other sterols including oxysterol and sterol-acids in the absence of 485 
isotope-labelled standards 486 
In comparison to non-esterified oxysterols and acids, the number of analytes that can be semi-487 
quantified is reduced as a consequence of the lability of the 7-hydroxy-5-ene and 7-hydroxy-4-en-3-488 
one structures in strongly basic solutions and a lack of authentic isotope-labelled standards available 489 
to compensate for this. The data generated is presented in Table 1. 490 
3.2.4. Comparison of data for esterified and non-esterified sterols 491 
In agreement with earlier reports, about 25% of cholesterol is present in its non-esterified form [3], 492 
while levels of non-esterified side-chain hydroxycholesterols varied from about 10 – 25% [3, 19] (Table 493 
1). The % of non-esterified ring-oxidised sterols was higher, ranging from about 30% for 7-OC to 96% 494 
for 7α-HCO where there is no 3β-hydroxy group available for esterification. 3β-HCA was found to be 495 
essentially all in the free form; this is likely to be true for both epimers of 7αH,3O-CA where the % free 496 
form was in excess of 100%. The high % can be explained by the imperfect correction, even with the 497 
use of an authentic isotope-labelled standard, to account for loss of 7α-hydroxy-4-en-3-one analyte in 498 
strong base.      499 
In summary, in addition to the 17 free sterols quantified in section 3.1.3.1, 12 sterols, including 500 
oxysterols and cholestenoic acids were quantified as “total sterol” representing the sum of non-501 
esterified and esterified sterols. Semi-quantitative measurements were made on a further 5 sterols.  502 
3.3. Sterols including oxysterols and sterol-acids in CSF 503 
Non-esterified oxysterols are present in CSF at much lower concentrations (<1 ng/mL) than in plasma 504 
(ng/mL) [14, 39, 40]. However, cholestenoic acids are comparatively abundant in CSF [39, 40, 48]. 505 
Thus, if CSF material is limited in its availability, it may be optimal to analyse cholestenoic acids as the 506 
non-esterified entities in a volume of non-hydrolysed CSF and oxysterols following hydrolysis in a 507 
separate volume. 508 
First, we confirmed the linearity of eq. 1 in CSF (100 µL) using 20 µL of OxysterolSPLASH in a standard 509 
addition experiment over a 5-fold concentration range (Supplemental Table S3B). All analytes targeted 510 
by OxysterolSPLASH gave R2 > 0.99, except low abundance 7α,25-diHC (R2 > 0.98). This experiment 511 
also provided a value for experimental accuracy (>80% in all cases), where accuracy is defined as the 512 
agreement between actual measured concentration and that derived from eq.1, and apparent 513 
extraction efficiency (99% – 122%). Accuracy was least good for 7α,25-diHC and 7α,(25R/S)26-diHC 514 
where the concentration of internal standard is low and for 7α-HC that can be formed ex vivo from 515 
cholesterol by autoxidation. Again, we exploited technical dilutions of prepared samples to estimate 516 
a lower limit of quantification as the lowest concentration at which the measured concentration of 517 
analyte differs from the calculated concentration by less than 30%.  518 
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Additional experiments were performed in which the volumes of CSF and OxysterolSPLASH were 519 
reduced. There was consequent reduction in signal for both analytes and standard and these 520 
experiments were not perused further.      521 
3.3.1. Non-esterified sterols including oxysterols and sterol-acids in CSF 522 
Using 20 µL of OxysterolSPLASH to provide the isotope-labelled standard, the 25R and 25S epimers of 523 
7αH,3O-CA can be reliably quantified from 100 µL of non-hydrolyzed CSF (%CV < 20%) and by 524 
considering data in fraction-A and fraction-B, so can the individual epimers of 3β,7αH-diHCA (%CV < 525 
20%, Table 2, Figure 4A & B). Increasing the volume of CSF to 200 µL gave data of similar precision. 526 
Cholesterol is likewise measured by reference to added isotope-labelled standard with acceptable 527 
precision (%CV <10%). We did not attempt to quantify 7α-HC, 7β-HC, 7-OC or 5α,6β-diHC in CSF, as 528 
they can be formed by ex vivo autoxidation of cholesterol. Even a small degree of ex vivo autoxidation 529 
will introduce major errors in quantification when the endogenous molecules are of low abundance.      530 
In addition to the 4 cholestenoic acids and cholesterol quantified by direct reference to isotope-531 
labelled surrogates, we also obtained semi-quantitative data on another 5 sterol-acids and two sterols 532 
in the absence of authentic isotope-labelled standards (Figure 4B & C), and approximate quantification 533 
on a further two sterol-acids and one oxysterol, partially identified in the absence of internal standards 534 
(Table 2). 535 
3.3.2. Esterified sterols and oxysterols in CSF 536 
As in plasma, oxysterols found in CSF are present as free alcohols and esterified to fatty acids. By 537 
extracting oxysterols in 0.35 M KOH in ethanol the esters are hydrolysed, allowing measurement of 538 
“total” oxysterols. In this way 24S-HC, 25-HC, (25R)26-HC and 7α,(25R/S)26-diHC could be reliably 539 
measured (%CV < 20%) from 100 µL of CSF (Table 2, Figure 4D & 4E). 7α,25-diHC could also be 540 
measured but at lower precision (%CV < 30%). Other 7-hydroxy-5-ene or 7-hydroxy-4-en-3-one 541 
compounds were not reliably measured in the absence of the exact isotope labelled surrogate. 542 
The current data set for 100 µL of CSF and 20 µL of OxysterolSPLASH was compared to data generated 543 
using the same CSF sample but exploiting quantitative isotope-labelled standards [2H6]24R/S-HC and 544 
[2H7]cholesterol. Using [2H6]24R/S-HC as an internal standard for 24S-HC, 25-HC and (25R)26-HC, the 545 
agreement between the methods was good for 24S-HC and (25R)26-HC (>96%) but only moderate for 546 
low abundance 25-HC (51%). The agreement of cholesterol measurements was also good at 91%.   547 
Table 2. Analysis of non-hydrolysed and hydrolysed CSF. 548 
3.4. Quantification of oxysterols in patient samples 549 
3.4.1. ACOX2 550 
Mass spectrometry is an ideal method to diagnose inborn errors of cholesterol metabolism [8]. One 551 
such disorder is ACOX2 deficiency [10]. ACOX2 is a peroxisomal enzyme involved in the side-chain 552 
shortening of C27 to C24 acids as part of the bile acid biosynthesis pathways (see [49] for details of 553 
metabolic pathways). Its substrates are CoA thioesters of C27 acids with 25S-steriochemistry, which 554 
themselves are derived from the corresponding CoA thioesters with 25R-steriochemistry in a reaction 555 
catalysed by alpha-methylacyl-CoA racemase (AMACR) [50]. Plasma analysis of bile acid precursors 556 
reveals C27 acids rather than their CoA thioesters, hence, it is anticipated that 3β,7α-diHCA(25S) and 557 
7αH,3O-CA(25S) should be elevated in plasma from patients with ACOX2 deficiency. The availability 558 
of the [2H3]-labelled forms 7αH,3O-CA(25S) and 7αH,3O-CA(25R) allows quantification using the 559 
EADSA method of these two endogenous acids and also of 3β,7α-diHCA(25S) and 3β,7α-diHCA(25R) 560 
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(Table 1 and Figure 5A & 5B). In normal plasma the two 25R-epimers are about three and six times 561 
more abundant than the 25S-epimers, but in plasma from the ACOX2 deficient patient the 25S-562 
epimers are more abundant, confirming the biochemical phenotype of the patient. It is also 563 
noteworthy that the ratio of 3β,7β-diHCA(25R) to 3β,7β-diHCA(25S) in an ACOX2 heterozygote is 564 
seven, while in the ACOX2 deficient patient only about two (Table 1). This suggests that 3β,7β-565 
diHCA(25S) as the Co-A thioester is a substrate for ACOX2, which provides a route to side-chain 566 
shortened 7β-hydroxy C24 bile acids, usually characterised as secondary bile acids [43]. 567 
ACOX2 deficiency is one of a number of peroxisomal disorders which present to differing extents with 568 
cholestatic liver disease in infants and children [8, 51]. It is known that 3β-hydroxy-5-ene and 3-oxo-569 
4-ene C24 acids can inhibiting the bile acid export pump [52] and we speculate that the corresponding 570 
C27 acids may similarly inhibit the export pump and contribute to infantile/childhood cholestasis in 571 
peroxisomal disorders. It will be interesting to study if infants with these high C27 acids are those that 572 
develop cholestasis.       573 
3.4.2. CTX 574 
CTX results from a deficiency of CYP27A1 the enzyme that introduces the (25R)26-hydroxy and 575 
(25R)26-carboxylate functions to the sterol skeleton [8], see [49] for details of metabolic pathways. 576 
The result is an absence of (25R)26-HC in plasma and an elevation in 7α-HCO [31, 53]. This is evident 577 
in Figure 5C which shows a RIC for monohydroxycholesterols and monohydroxycholestenones in a 578 
plasma sample from a CTX patient. Note the absence of a peak corresponding to (25R)26-HC in the 579 
RIC for monohydroxycholesterols and that 24R-HC becomes evident without the need to plot a specific 580 
MRM chromatogram targeting 24R/S-HC cf. Figure 2A lower panel. The availability of both the 581 
[2H7]24R-HC and [2H7]24S-HC standards allows the definitive identification of these epimers in human 582 
plasma and also their quantification. A similar pattern of monohydroxycholesterols was revealed upon 583 
analysis of CSF from CTX patients following hydrolysis. It is also of interest to explore the RIC of 584 
7αH,3O-CA (Figure 5D). Surprisingly, both 25R and 25S epimers are present in the CTX sample at about 585 
equal levels, in stark contrast to the situation in the NIST SRM 1950 sample where the 7αH,3O-CA(25R) 586 
epimer is dominant (Figure 5D). This finding will be discussed in more detail in a future report.          587 
4. Discussion 588 
Stable isotope dilution MS with the use of authentic isotope-labelled standards represents the most 589 
reliable method for sterol quantification [18, 19]. Here we have utilised a recently introduced 590 
commercial mixture of standards (OxysterolSPLASH) to make quantitative measurements on the NIST 591 
SRM 1950 plasma sample. Unsurprisingly, we achieve good agreement when utilising the standard 592 
mix or when using an in-house mixture of isotope-labelled standards. The data generated in this study 593 
for hydrolysed plasma can be compared to that provided by NIST for cholesterol and to work from 594 
McDonald et al who measured cholesterol and other oxysterols [22, 45]. The cholesterol 595 
concentration determined in the current study 1.541 mg/mL agrees well with both the NIST value of 596 
1.514 mg/mL and that of McDonald et al 1.45 mg/mL [22, 45]. Similarly, there is good agreement with 597 
the values determined here and those by McDonald et al for most oxysterols(Table 1). Although we 598 
took considerable care to minimise ex vivo autoxidation of cholesterol and avoid artefactual formation 599 
of oxysterols, this can never be fully achieved when samples are prepared in air, and this is reflected 600 
in the poorer performance of the analytical method in terms of precision for 7β-HC, 7-OC and 5α,6β-601 
diHC, and in the lesser agreement between measured values when using different batches of standard 602 
also for 7α-HC. 7β-HC, 7α-HC and 7-OC can all be formed by non-enzymatic free radical autoxidation 603 
reactions [49, 54]. This is also true of 5,6-epoxycholesterol the ex vivo precursor of 5α,6β-diHC. 604 
Although not using the same plasma it is interesting to compare the % of free sterol determined here 605 
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for NIST SRM 1950 and by Dzeletovic et al in their classic study where 31 plasma samples were 606 
investigated (Table 1) [19]. In both studies the % of free 24S-HC was about 25%, (25R)26-HC about 607 
10%, 7α-HC about 20%, while values for 7-OC were higher at 30 – 60%. 608 
In the present study we have “deep mind” the NIST SRM 1950 plasma in terms of sterol identification 609 
and quantification (see Table 1 and Supplemental Table S1). We only report absolute quantification 610 
for those sterols for which an isotope-labelled authentic standard was included. This gave data for 17 611 
sterols, with another 8 sterols semi-quantified without using an authentic isotope-labelled standard, 612 
while one further sterol was approximately quantified but only partially identified. In addition, 7 other 613 
sterols were identified but not quantified while 8 additional sterols were partially identified. While 614 
this study covers most of the cholesterol metabolites routinely analysed in plasma [46], many more 615 
are present at lower levels and may only be revealed in patients suffering from inborn errors of 616 
cholesterol metabolism, biosynthesis or transport [24-28, 55, 56]. For comparison McDonald and 617 
colleagues have also “mined” NIST SRM 1950 plasma by LC-MS for oxysterols. In one study they 618 
quantified 8 oxysterols, both in the non-esterified form and as the total of non-esterified plus 619 
esterified forms [3], and in a later study 10 oxysterols, cholesterol and 6 precursors as the combination 620 
of non-esterified and esterified forms [45].           621 
Besides analysing plasma, we have also explored the use of the standard mix to quantify oxysterols in 622 
a QC sample of CSF. As levels of most non-esterified oxysterols are low in CSF (< 1 ng/mL) [14, 39, 40, 623 
57] we have analysed CSF in a non-hydrolysed and hydrolysed form. The non-hydrolysed form reveals 624 
non-esterified cholestenoic acids which are relatively abundant (Table 2), while the hydrolysed sample 625 
reveals oxysterols which are released as alcohols from their fatty acyl esters by strong base. It is of 626 
interest to note the comparatively high levels of both 25R and 25S epimers of 7αH,3O-CA in the QC 627 
CSF sample. In our previous studies, only the combined value for both epimers has been measured 628 
[39, 40, 57] using [2H7]24R/S-HC as the internal standard. Saeed et al reported the concentration of 629 
7αH,3O-CA in CSF samples from patients with headache, suffering from Alzheimer’s disease or from 630 
vascular dementia to be about 15 ng/mL [48], which is in good agreement with that reported here of 631 
about 20 ng/mL for our QC sample. Importantly, as in the current study, Saeed et al used an authentic 632 
isotope-labelled standard [48]. They used [25,27,27,27-2H4]7αH,3O-CA which should have exclusively 633 
25R-stereochemistry as it was derived by CYP27A1 oxidation of [25,26,26,26,27,27,27-2H7]7α-HCO 634 
[48]. Saeed et al emphasised the importance of the use of an authentic isotope-labelled standard, 635 
which is particularly important for compounds with a 7-hydroxy-3-oxo-4-ene structure that are labile 636 
to both acid and base catalysed dehydration [43, 48]. 637 
In the hydrolysed CSF sample we analysed 24S-HC, 25-HC, (25R)26-HC, 7α,25-diHC and 7α,(25R/S)26-638 
diHC and the values we report for our QC sample are in general agreement with those in the literature 639 
for 24S-HC and (25R)26-HC [7], we could not find literature values for 25-HC, 7α,25-diHC or 640 
7α,(25R/S)26-diHC following base hydrolysis [58, 59]. There appear to be few reported values for other 641 
oxysterols in CSF. In the current study we did not analyse 7α-HC, 7β-HC or 5α,6β-HC due to the 642 
presence of late eluting contaminants resulting from the hydrolysis of other lipids. In previous studies 643 
we have measured monohydroxycholesterols in non-hydrolysed samples, however, to achieve this 644 
goal we needed to pre-concentrate samples [39, 40], something we have not done in this study. It 645 
should be noted, that at the low levels of oxysterols in non-hydrolysed CSF (<0.1 ng/mL) there is the 646 
possibility of significant analyte loss by absorption into plastics. To avoid this Sidhu et al have 647 
suggested addition of 2.5% 2-hydroxypropyl-β-cyclodextrin to CSF during collection [14]. 648 
Finally, with respect to the drive of the lipidomic community for standardisation [60],  we have made 649 
our best effort to report the figures of merit of the current methodology in terms of lower limit of 650 
quantification, linearity of response, apparent extraction efficiency, accuracy and precision (see 651 
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Supplemental Table S3 and Table 1) . We also make our data publicly available in a data repository 652 
(OFS, Center for Open Science).    653 
In summary, we report here the absolute and semi-quantification of sterols, including oxysterols and 654 
cholestenoic acids in NIST SRM 1950 plasma and in a laboratory QC CSF sample. Where available, the 655 
data generated is in good agreement with other studies. The current report extends the range of 656 
sterols that can be routinely measured in plasma and CSF samples. 657 
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Figure Captions 672 
Figure 1. Schematic depicting the EADSA method. In fraction-A cholesterol oxidase converts 3β-673 
hydroxy-5-ene functions to 3-oxo-4-ene groups which are derivatised with [2H5]GP. Any natural 3-oxo-674 
4-ene containing sterols will be similarly derivatised with [2H5]GP. In fraction-B cholesterol oxidase is 675 
absent so only oxosterols, e.g. 3-oxo-4-enes (and 7-oxo-5-enes), will become derivatised, in this case 676 
with [2H0]GP. Deconvolution of data from fractions-A and -B provides the quantities of sterols with an 677 
original 3β-hydroxy-5-ene function (i.e. A-B), while fractions-B provide quantities of oxosterols. 678 
Figure 2. LC-MS separation of GP-derivatised monohydroxycholesterols (HC). (A) Upper panel, RIC of 679 
the [M]+ ions of monohydroxycholesterols (539.4368 ± 5 ppm) found in plasma. Lower panel, MRM 680 
539.4→455.4→353.3 characteristic of 24R/S-HC. The red dashed line indicates the coincidence of 24S-681 
HC in the upper and lower panels and the black dashed lines indicates where 24R-HC partially overlaps 682 
(in time, but not in MRM) with (25R)26-HC. (B) Upper panel, RICs for [2H7]-labelled 683 
monohydroxycholesterols (546.4807 ± 5 ppm). The green arrow indicated the distortion in the 684 
[2H7]24R-HC chromatographic peak as a consequence of the co-eluting and mass spectrometrically-685 
unresolved [M+1]+ ion of [2H6](25R)26-HC (m/z  546.4777). Lower panel, MRM 546.5→462.4→353.3 686 
characteristic of [2H7]24R/S-HC. Note the fragment ion at m/z 353.3 is also evident in MS3 spectra of 687 
[2H7]22R/S-HCO. Coloured dashed lines indicate the coincidence of peaks of the same oxysterol. (C) 688 
Upper panel, RICs for [2H6]-labelled monohydroxycholesterols (545.4744 ± 5ppm). Lower panel total 689 
ion chromatogram (TIC) 545.5→461.4→ for [2H6]-labelled monohydroxycholesterols. (D) RIC for 690 
monohydroxycholesterols in plasma (upper panel) and [2H7]-labelled standards (lower panel) recorded 691 
on a shorter chromatographic time scale. (E) RIC for monohydroxycholestenones in plasma (534.4054 692 
± 5ppm) and [2H7]-labelled standards (541.4493 ± 5ppm). Note in all chromatograms the deuterium 693 
labelled oxysterols elute slightly earlier than their non-labelled analogues. Relevant MS3 spectra are 694 
presented in Supplemental Figures S3 & S5. 695 
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Figure 3. LC-MS separation of GP-derivatised dihydroxycholesterols (diHC), dihydroxycholestenones 696 
(diHCO), dihydroxycholestenoic (diHCA) and hydroxyoxocholestenoic (H,O-CA) acids. (A) RIC for the 697 
[M]+ ions of (upper panel) 7α,25-diHC + 7α,25-diHCO and 7α,(25R/S)26-diHC + 7α,(25R/S)26-diHCO 698 
(555.4317 ± 5 ppm) found in plasma, and (lower panel) [2H6]7α,25-diHC and [2H6]7α,(25R/S)26-diHC 699 
(561.4694 ± 5 ppm) over a 17 min gradient. (B) MS3 ([M]+→[M-Py]+→) TICs for (upper panel) 7α,25-700 
diHC + 7α,25-diHCO and 7α,(25R/S)26-diHC + 7α,(25R/S)26-diHCO (555.4→471.4→) found in plasma 701 
and (lower panel) [2H6]7α,25-diHC and [2H6]7α,(25R/S)26-diHC (561.5→477.4→) over a 17 min, 702 
gradient. Note the additional peaks in the upper panel labelled by green arrows arise from 703 
fragmentation of the [M+2]+ peaks with monoisotopic m/z of 553.4161. In the sterol structures R1 is 704 
OH in 7α,25-diHC and R2 is OH in 7α,(25R/S)26-diHC. (C) RIC for the [M]+ ions (550.4003 ± 5 ppm, upper 705 
panel) and TICs for the MS3 fragmentation (550.4→471.4→, lower panel) of 7α,25-diHCO and 706 
7α,(25R/S)26-diHCO found in plasma. Note the additional peak in the lower panel labelled by the 707 
green arrow arises from fragmentation of the [M+2]+ peak with monoisotopic m/z 548.3847. (D) RIC 708 
for the [M]+ ions of (upper panel) 7αH,3O-CA(25R/S) (564.3796 ± 5 ppm) found in plasma and (lower 709 
panel) [2H3]7αH,3O-CA(25R/S) (567.3984 ± 5 ppm) over a 17 min gradient. (E) RIC for the [M]+ ions of 710 
(upper panel) 7αH,3O-CA(25R/S) + 3β,7α-diHCA(25R/S) (569.4110 ± 5 ppm) found in plasma and 711 
(lower panel) [2H3]7αH,3O-CA(25R/S) (572.4298 ± 5 ppm) over a 17 min gradient. Coloured dashed 712 
lines indicate the coincidence of peaks of the same oxysterol. Chromatograms recorded over a 37 min 713 
gradient can be found in Supplemental Figure S6. MS3 spectra are presented in Supplemental Figures 714 
S7 & S8. 715 
Figure 4. LC-MS separation of GP-derivatised cholestenoic acids, and mono- and 716 
dihydroxycholesterols in CSF. (A) RIC for the [M]+ ions of (upper panel) 7αH,3O-CA(25R/S) (564.3796 717 
± 5 ppm) found in CSF, and (lower panel) [2H3]7αH,3O-CA(25R/S) (567.3984 ± 5 ppm). (B) RIC for the 718 
[M]+ ions of (upper panel) 7αH,3O-CA(25R/S) + 3β,7α-diHCA(25R/S) (569.4110 ± 5 ppm) found in CSF, 719 
and (lower panel) [2H3]7αH,3O-CA(25R/S) (572.4298 ± 5 ppm). In (A) the derivatisation agent was 720 
[2H0]GP and in (B) [2H5]GP. (C) RIC for the [M]+ ions of diH,3O-CA isomers (585.4059 ± 5 ppm) found in 721 
CSF (upper panel), note the triHCA equivalents are absent. TIC for the MS3 fragmentation 722 
(585.4→501.3→) for diH,3O-CA isomers (2nd panel). MRM (585.4→501.3→427.3) targeting 7α,24-723 
diH,3O-CA (3rd panel), and MRM (585.4→501.3→455.3) targeting 7α,25-diH,3O-CA (bottom panel). 724 
See Supplemental Figures S4P & S4Q for relevant fragmentation schemes. Chromatograms in (A – C) 725 
are from non-hydrolysed CSF. (D) RIC of the [M]+ ions of monohydroxycholesterols (539.4368 ± 3 ppm) 726 
found in CSF (upper panel). RIC (546.4807 ± 3 ppm) for [2H7]24R/S-HC, [2H7]7β-HC, [2H7]7α-HC and 727 
dehydrated [2H7]5α,6β-diHC (central panel). RIC (545.4744 ± 3 ppm) for [2H6]25-HC and [2H6](25R)26-728 
HC (lower panel). (E) TIC for the MS3 fragmentations (555.4→471.4→) of 7α,25-diHC and 729 
7α,(25R/S)26-diHC found in CSF (upper panel) and for the fragmentations (561.5→477.4→) of 730 
[2H6]7α,25-diHC and [2H6]7α,(25R/S)26-diHC.  Chromatograms (D & E) are for hydrolysed CSF. 731 
Coloured dashed lines indicate the coincidence of peaks of the same oxysterol. All chromatograms 732 
were recorded over a 17 min gradient. 733 
Figure 5. LC-MS separation of GP-derivatised cholestenoic acids, monohydroxycholesterols and 734 
monohydroxycholestenones in plasma samples representative of the inborn errors of cholesterol 735 
metabolism ACOX2 deficiency and CTX. (A) RIC (564.3796 ± 5 ppm) for [M]+ ions corresponding to 736 
7αH,3O-CA(25R/S) in NIST SRM 1950 plasma (upper panel), from a patient suffering from ACOX2 737 
deficiency (central panel), and the RIC (567.3984 ± 5 ppm) corresponding to the [M]+ ion of 738 
[2H3]7αH,3O-CA(25R/S) (lower panel). (B) RIC (569.4110 ± 5 ppm) for [M]+ ions corresponding to 3β,7α-739 
diHCA(25R/S) + 7αH,3O-CA(25R/S) in NIST SRM 1950 plasma (upper panel), from a patient suffering 740 
from ACOX2 deficiency (central panel), and the RIC (572.4298 ± 5 ppm) corresponding to the [M]+ ion 741 
of [2H3]7αH,3O-CA(25R/S) (lower panel). Samples in (A) have been treated with [2H0]GP and those in 742 
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(B) with [2H5]GP. (C) RIC (539.4368 ± 5 ppm) for [M]+ ions corresponding to monohydroxycholesterols 743 
and monohydroxycholestenones in NIST SRM 1950 plasma (upper panel), from a sample from a 744 
patient suffering from CTX (central panel), and the RIC (546.4807 ± 5 ppm) corresponding to the [M]+ 745 
ion of [2H7]24R/S-HC (lower panel). (D) RIC (564.3796 ± 5 ppm) for [M]+ ions corresponding to 7αH,3O-746 
CA(25R/S) in NIST SRM 1950 plasma (upper panel), from a sample from a patient suffering from CTX 747 
(central panel), and the RIC (567.3984 ± 5 ppm) corresponding to the [M]+ ion of [2H3]7αH,3O-748 
CA(25R/S) (lower panel). Coloured dashed lines indicate the coincidence of oxysterols between 749 
chromatograms. 750 
Table Captions 751 
Table 1. Sterols including oxysterols and sterol-acids quantified, semi-quantified or approximately 752 
quantified in human plasma. 753 
Table 2. Analysis of non-hydrolysed and hydrolysed CSF. 754 
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SRM 1950 7αH,3O-CA(25S), 14.2 ng/mL
ACOX2 7αH,3O-CA(25S), 262.4 ng/mL
%RA
ey_200718_100ul_nist_qc_plasma(2018)_... 07/19/20 07:41:18
RT: 0.00 - 37.01



































m/z= 539.4352-539.4384 F: FTMS + p 





m/z= 539.4352-539.4384 F: FTMS + p 





m/z= 546.4791-546.4823 F: FTMS + p 

















SRM 1950 (25R)26-HC, 24.1 ng/mL
7α-HC + 7αHCO, 47.4 ng/mL
CTX (25R)26-HC, 0.0 ng/mL




















non-hydrolysed Clayton Acox/ Tubingen Ctx Plasma
RT: 0.00 - 17.02



































m/z= 564.3779-564.3813 F: FTMS + p 





m/z= 564.3779-564.3813 F: FTMS + p 





m/z= 567.3967-567.4001 F: FTMS + p 





























SRM 1950 7αH,3O-CA(25R), 85.0 ng/mL
CTX 7αH,3O-CA(25R), 2.3 ng/mL
EY_200718_100ul_NIST_QC_Plasma(2018)_... 07/19/20 08:42:42
RT: 0.00 - 17.02



































m/z= 569.4082-569.4138 F: FTMS + p 





m/z= 569.4082-569.4138 F: FTMS + p 





m/z= 572.4269-572.4327 F: FTMS + p 
































SRM 1950 3β,7α-diHCA(25S), 11.6 ng/mL















































Cholesterol Q NM NA 402,515 3 NM NA NA NA 402,515 NM NM NM Q NM NA 1,541,364 3.81 NA 1,541,364 1,450,000 1,450,000 26.11 21.8
Desmosterol SQA NM NA 235.40 4 NM NA NA NA 235.40 NM NM NM SQ NM NA 1,442 8.07 NA 1,442 722 696 16.33
8,9-Dehydrocholesterol SQA NM NA 428.55 1 NM NA NA NA 428.55 NM NM Nm SQ NM NA 1,927 4.07 NA 1,927 1,138 1,160 22.24
3βH-Δ5-BA SQ 4.01 4 3.90 10 NM NA 97.24 NA 3.96 NM NM NM SQ 5.17 12.80 5.23 5.45 98.83 5.20 76.19
3β,7β-diH-Δ5-BA SQ 2.21 9 2.39 14 NM NA 92.41 NA 2.29 NM NM NM B NM NA NM NA NA NA
3β,7α-diH-Δ5-BA SQ 4.18 10 3.42 27 NM NA 81.61 NA 3.84 NM NM NM B NM NA NM NA NA NA
7αH,3O-Δ4-BA SQ 5.37 4 6.55 24 NM NA 81.99 NA 5.90 NM NM NM SQC 6.30 20.86 4.29 25.38 68.03 5.29 111.41
7αH,27-nor-C-3,24-diO AQ 0.69 16 0.76 31 NM NA 90.20 NA 0.72 NM NM NM NM NA NM NA NM NA
24S-HC Q 9.33 2 9.01 1 8.88 9.5 96.56 98.54 9.19 12.85 47.35 17.19 Q 39.91 1.70 40.05 5.59 99.66 39.98 44.6 22.99 12.9 28
25-HC Q 1.13 11 1.05 11 0.96 24.2 93.01 91.43 1.10 2.05 4.26 1.36 Q 6.20 8.27 6.49 5.12 95.66 6.35 5.7 17.28 4.4 41
(25R)26-HC Q 24.17 2 24.02 2 22.20 13.7 99.39 92.39 24.11 31.31 32.23 0.00 Q 185.44 3.47 187.42 2.86 98.94 186.43 131 12.93 2.4 9
7β-HC Q 3.02 11 2.88 5 2.70 27.9 95.22 93.85 2.96 27.78 39.12 54.37 Q 9.07 11.01 7.79 39.67 85.89 8.43 35.09 15
7-OC Q 11.21 33 6.85 29 6.52 35.5 61.16 95.11 9.27 163.04 114.68 118.60 Q 28.95 71.12 30.04 76.75 96.39 29.50 24 31.43 11.2 62
7α-HC + 7α-HCO 48.65 6 45.83 6 36.18 15.2 94.21 78.94 47.40 153.92 45.54 707.21 104.87 8.44 117.92 17.10 88.93 111.39 42.55
7α-HC Q 21.00 14 21.99 16 10.72 22.1 95.54 48.78 21.44 51.88 27.26 NM Q 76.68 8.24 92.17 21.57 83.19 84.42 91.8 25.40 3.5 17
7α-HCO Q 27.65 7 23.85 12 25.46 18.2 86.26 93.67 25.96 102.04 18.29 NM Q 28.19 10.02 25.75 26.15 91.35 26.97 96.25
5α,6β-diHC QD 2.91 16 4.68 25 3.87 97.3 62.28 82.66 3.70 NM NM NM E 7.16 40.39 10.85 69.59 65.95 9.01 41.05
7α,25-diHC + 
7α,25-diHCO
A 1.91 6 1.97 3 1.84 33.3 97.04 93.45 1.94 NM NM NM NM NA NM NA NA NA
7α,25-diHC NDA ND NA ND NA ND NA NA NA NA NM NM NM Q 1.13 5.74 0.94 20.59 82.58 1.04
7α,25-diHCO QA 1.96 5 1.88 10 1.69 34.1 96.09 89.98 1.92 NM NM NM B NM NA NM NA NA NA
7α,(25R/S)26-diHC + 
7α,(25R/S)26-diHCO
A 7.68 2 7.19 6 7.31 19.6 93.53 98.38 7.46 NM NM NM NM NA NM NA NA NA
7α,(25R/S)26-diHC NDA ND NA ND NA ND NA NA NA NA NM NM NM Q 6.94 8.47 6.36 12.21 91.68 6.65 9.6
7α,(25R/S)26-diHCO QA 7.94 9 7.40 9 6.93 18.4 93.21 93.57 7.70 NM NM NM B NM NA NM NA NA NA
3β-HCA SQ 133.11 2 112.78 7 119.05 19.9 84.73 94.73 124.08 107.87 348.14 SQ 119.67 2.50 122.76 3.27 97.48 121.22 102.36
3β,7β-diHCA(25R/S) SQF 10.06 6 8.17 9 6.98 16.4 81.15 85.47 9.22 9.45 105.59 NM NA NM NA NA NA
3β,7β-diHCA(25S) SQ MN NA NM NA NM NA NA NA NA 1.22 31.76 NM NA NM NA NA NA
3β,7β-diHCA(25R) SQ MN NA NM NA NM NA NA NA NA 8.23 73.83 NM NA NM NA NA NA
3β,7α-diHCA(25R/S) + 
7αH,3O-CA(25R/S) 
F 139.42 1 142.31 3 102.88 19.0 97.97 72.30 140.70 176.83 801.19 B NM NA NM NA NA NA
3β,7α-diHCA(25R/S) F 44.33 5 38.13 13 29.56 19.5 86.01 77.53 41.57 29.06 314.17 B NM NA NM NA NA NA
7αH,3O-CA(25R/S) F 95.09 1 104.18 7 73.32 18.9 91.27 70.38 99.13 147.76 487.02 C 85.88 4.60 69.99 6.66 81.51 77.93 127.19
3β,7α-diHCA(25S) + 
7αH,3O-CA(25S) 
F 24.34 6 27.50 4 18.52 19.4 88.50 67.34 25.74 28.96 445.44 B NM NA NM NA NA NA
3β,7α-diHCA(25S) QF 10.95 15 12.39 14 8.56 24.5 88.36 69.09 11.59 9.05 183.06 B NM NA NM NA NA NA
7αH,3O-CA(25S) QF 13.39 3 15.11 7 9.96 19.5 88.61 65.91 14.15 19.91 262.38 1.80 QC 11.44 9.06 9.27 8.49 81.02 10.35 136.72
3β,7α-diHCA(25R) + 
7αH,3O-CA(25R) 
F 115.08 2 114.81 4 84.36 23.6 99.76 73.48 114.96 147.86 355.75 B NM NA NM NA NA NA
3β,7α-diHCA(25R) QF 33.38 9 25.74 20 21.00 29.2 77.11 81.59 29.99 20.01 131.11 B NM NA NM NA NA NA
7αH,3O-CA(25R) QF 81.70 1 89.07 8 63.36 22.1 91.72 71.14 84.97 127.85 224.64 2.29 QC 74.44 5.48 60.73 7.79 81.58 67.58 125.73
Hydrolysed plasma % Free sterols
% Accord 
between 









100 µL SRM 
1950 with 50 
µL SPLASH 
(n=4)




















100 µL SRM 
1950 with 50 µL 
SPLASH (n=5)
Non-hydrolysed plasma
Colour coding according to standard used for quantification
Oxysterols and sterol acids are arranged according to mass and retention time
Abbreviations
ID/Quan, Identified or quantified
Q, quantified against isotope labelled standard
SQ, semi-quantified (authentic isotope labelled standard not available)





Italics  are used to indicate an ideal isotope labelled standard was not used 
Bold figures indicate quantities in ng/mL
(A) Determined by MS3
(B) Appropriate standard not available
(C) Base hydrolysis likely to introduce some error
(D) 5α,6β-diHC measured as its dehydration product 6β-HC
(E) Autoxidation likely under experimental conditions employed
(F) Individual standards do not include the appropriate isotope labelled standard  
Table 2. Analysis of non-hydrolyzed and hydrolysed CSF.
Sterols
















Cholesterol Q 1,512 6.46 Q 4,609 5.63 4,172 11.08 90.53 760.4 ± 269.9 4,500 39,6
Desmosterol SQ 3.88 16.59 SQ 8.07 7.62 NM NA NA
8,9-Dehydrocholesterol SQ 2.47 18.51 SQ 5.52 14.78 NM NA NA
7αH,3O-Δ4-BA SQ 1.04 25.03 NM NA NM NA NA 0.79 ± 0.23 39,
7αH-27-nor-C-3,24-diO AQ 2.01 23.22 NM NA NM NA NA 0.79 ± 0.14
24S-HC ND NA Q 1.70 3.80 1.73 13.87 98.17 1.4 ± 0.5 7,
25-HC ND NA Q 0.13 19.41 0.07 24.03 50.79
(25R)26-HC ND NA Q 1.18 7.84 1.14 10.54 96.55 0.5 ± 0.1 7,
7α,25-diHC ND NA QA 0.05 27.65 NM NA NA
7α,(25R/S)26-diHC ND NA QA 0.17 9.67 NM NA NA
3β-HCA SQ 3.42 20.66 1.45 ± 0.62 (2) 39, (12)
3β,7β-diHCA(25R/S) SQB 0.59 11.17 0.74 ± 0.28 39,
3β,7α-diHCA(25R/S) Q 4.62 14.05 3.99 ± 2.55 39,
7αH,3O-CA(25R/S) Q 23.72 8.02 25.6 ± 7.77 (15 ± 3) 39, (48)
3β,7α-diHCA(25S) Q 1.68 17.48
7αH,3O-CA(25S) Q 4.98 18.34
3β,7α-diHCA(25R) Q 2.94 15.25
7αH,3O-CA(25R) Q 18.74 6.95
7α,24-diH,3O-CA SQ 0.27 23.05 0.38 ± 0.07 39,
7α,x-diH,3O-CA AQ 5.44 9.54 6.41 ± 1.72 39,
7α,25-diH,3O-CA SQ 1.62 14.00 2.04 ± 0.61 39,
7α,12α-diH,3O-CA AQ 0.75 10.04 1.13 ± 0.86 39,
Oxysterols and sterol acids arranged according to mass and retention time 
Colour coding according to standard used for quantification
Abbreviations
ID/Quan, Identified or quantified
Q, quantified against isotope labelled standard
SQ, semi-quantified (authentic isotope labelled standard not available)
AQ, approximately quantified in the absence of standard compound
100 µL CSF with 
20 µL SPLASH  
(n=9)
100 µL CSF with 
20 µL SPLASH  
(n=9)
CSF Literature ValuesNon-hydrolysed CSF
100 µL CSF with 






(B) 25R and 25S epimers quantified in combination
Reference
[7] Bjorkhem et al Neurosci Lett 555 (2013) 102-5
[39] Abdel-Khalik et at J Lipid Res 58(1) (2017) 267-278
[6] Leoni et al  J Lipid Res 46(2) (2005) 191-5
[12] Schols L et al Brain 140(12) (2017) 3112-3127
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Flowchart 1. Schematic illustration of sample preparation. Single-phase liquid extraction is performed 
into ethanol containing internal standards in the presence or absence of 0.35 M KOH. 
Flowchart 2. Different protocols for single-phase liquid extraction. 
Flowchart 3. Flowchart showing sterol identification and quantification routine. 
Supplemental Figures and Tables 
Figure S1. Syn (Z) and anti (E) conformers of the GP-derivative exemplified for 24S-HC. Also shown are 
3D minimised energy structures (Chem 3D Pro). MS2 fragmentation results in loss of the pyridine (Py) 
group with the formation of the [M-Py]+ fragment ion. 
Figure S2. LC-MS separation of GP-derivatised monohydroxycholesterols (HC). (A) Mass spectrometric 
peaks at m/z 546.48 corresponding to the [M]+ ion of [2H7]24S-HC (upper panel); the [M+1]+ ion of 
[2H6]26-HC (lower panel); and unresolved [M]+ ion of [2H7]24R-HC and the [M+1]+ ion of [2H6]26-HC 
(central panel). The structure of the [M+1]+ ion of [2H6]26-HC is arbitrarily drawn with a 13C at C-21. (B) 
Upper panel, TIC 534.4→455.4→ for monohydroxycholestenones in plasma. Lower panel TICs 
541.5→462.4 for [2H6]-labelled monohydroxycholesterols. 
Figure S3. MS3 fragmentation of GP-derivatised monhydroxycholesterols in plasma. MS3 ([M]+→[M-
Py]+→) spectra of (A) 24S-HC; (B) 24R-HC; (C) [2H7]24S-HC; (D) [2H7]24R-HC; (E)25-HC; (F) [2H6]25-HC; 
(G) (25R)26-HC; (H) [2H6](25R)26-HC; (I) [2H7]22R-HC; (J) 22S-HC; (K) [2H7]22S-HC. The formation of key 
fragment ions is illustrated in Figure S4A-D. 
Figure S4. Key fragmentation routes in the MSn spectra of GP-derivatised oxysterols. (A) 24R/S-HC and 
[2H6]24R/S-HC; (B) 25-HC and [2H6]25-HC; (C) (25R)26-HC and [2H6](25R)26-HC; (D) 22R/S-HC and 
[2H7]22R/S-HC; (E) 7-HC and [2H7]7-HC; (F) 6β-HC and [2H7]6β-HC; (G) 7-OC and [2H7]7-OC; (H) 12α-HC; 
(I) 7α,25-diHC and [2H6]7α,25-diHC; (J) 7α,(25R/S)26-diHC and [2H6]7α,(25R/S)26-diHC; (K) 7α,12α-
diHC; (L)  3β,7-diHCA(25R/S) and [2H3]3β,7-diHCA(25R/S); (M) 25-D3 and [2H6]25-D3; (N) 3βH-Δ5-BA and 
3β,7-diH-Δ5-BA; (O) 3β-HCA; (P) 3β,7α,24-triHCA; (Q) 3β,7α,25-triHCA; (R) 3β,7α,12α-triHCA; (S) 3β,25-
diHCA and 3β,22,25-triHC-24O; (T) 3β,27-diHCA; (U) 3β,22,25-triHC-24O; (V) 3β,22-diHC-24O.    
Figure S5. MS3 fragmentation of GP-derivatised monohydroxycholesterols and 
monohydroxycholestenones in plasma. MS3 ([M]+→[M-Py]+→) spectra of (A) 7β-HC; (B) [2H7]7β-HC; 
(C) 7α-HC; (D) [2H7]7α-HC; (E) 6β-HC (5α,6β-diHC-18), generated from the acid catalysed dehydration 
of 5α,6β-diHC; (F) [2H7]6β-HC ([2H7]5α,6β-18) generated from the acid catalysed dehydration of 
[2H7]5α,6β-diHC; (G) 7-OC; (H) [2H7]7-OC; (I) 7α-HCO; (J) [2H7]7α-HCO; (K) 12α-HC (no authentic 
standard). The formation of key fragment ions is illustrated in Figure S4E-H. 
Figure S6. LC-MS separation of GP-derivatised dihydroxycholesterols, monohydroxycholestenones 
(HCO), dihydroxycholestenoic (diHCA) and hydroxyoxocholestenoic (H,O-CA) acids. (A) RIC for the [M]+ 
ions of (upper panel) 7α,25-diHC + 7α,25-diHCO and 7α,(25R/S)26-diHC + 7α,(25R/S)26-diHCO 
(555.4317 ± 5 ppm) found in plasma and (lower panel) [2H6]7α,25-diHC and [2H6]7α,(25R/S)26-diHC 
(561.4694 ± 5 ppm) over a 37 min gradient. (B) RIC of the [M]+ ions of monohydroxycholestenones 
(550.4003 ± 5 ppm) found in plasma. Upper panel 37 min gradient, lower panel 17 min gradient. (C) 
RIC for the [M]+ ions of (upper panel) 7αH,3O-CA(25R/S) (564.3796 ± 5 ppm) found in plasma and 
(lower panel) [2H3]7αH,3O-CA(25R/S) (567.3984 ± 5 ppm) over a 37 min gradient. (D) RIC for the [M]+ 
ions of (upper panel) 7αH,3O-CA(25R/S) + 3β,7α-diHCA(25R/S) (569.4110 ± 5 ppm) found in plasma 
3 
 
and (lower panel) [2H3]7αH,3O-CA(25R/S) (572.4298 ± 5 ppm) over a 37 min gradient. Coloured dashed 
lines indicate the coincidence of oxysterols between chromatograms.    
Figure S7. MS3 fragmentation of GP-derivatised dihydroxycholesterols (diHC) and 
dihydroxycholestenones (diHCO) in plasma. MS3 ([M]+→[M-Py]+→) spectra of (A) 7α,25-diHC + 7α,25-
diHCO; (B) [2H6]7α,25-diHC; (C) 7α,(25S)26-diHC + 7α,(25S)26-diHCO; (D) [2H6]7α,(25S)26-diHC; (E) 
7α,(25R)26-diHC + 7αH,(25R)26-diHCO; (F) [2H6]7α,(25R)26-diHC; (G) 7α,25-diHCO; (H) 7α,(25R)26-
diHCO; (I) 7α,12α-diHC. The formation of key fragment ions is illustrated in Figure S4I – S4K. 
Figure S8. MS3 fragmentation of GP-derivatised dihydroxycholestenoic (diHCA) and 
hydroxyoxocholestenoic (H,O-CA) acids in plasma. MS3 ([M]+→[M-Py]+→) spectra of (A) 3β,7β-
diHCA(25R); (B) 3β,7α-diHCA(25S) + 7αH,3O-CA(25S); (C) [2H3]3β,7α-diHCA(25S); (D) 3β,7α-
diHCA(25R) + 7αH,3O-CA(25R); (E) [2H3]3β,7α-diHCA(25R); (F) 7αH,3O-CA(25S); (G) 7αH,3O-CA(25R); 
(H) [2H3]7αH,3O-CA(25R). The formation of key fragment ions is illustrated in Figure S4L. 
Figure S9. LC-MS(MS3) of cholesterol and other lipophilic sterols in plasma. (A) RIC for the [M]+ ions of 
cholesterol (upper panel, 523.4419 ± 5 ppm), [2H7]cholesterol (central  panel, 530.4858 ± 5 ppm) and 
isomers of cholestadien-3β-ol (lower panel 521.4262 ± 5 ppm). MS3 ([M]+→[M-Py]+→) spectra of (B) 
cholesterol, (C) [2H7]cholesterol, (D) desmosterol (24-DHC) and (E) 8(9)-dehydrocholesterol (8-DHC). 
The formation of key fragment ions is illustrated in (F – H).  
Figure S10. LC-MS separation of GP-derivatised 25-hydroxyvitanin D3 and sterol-acids in plasma. (A) 
RIC for the [M]+ ions of 25-D3 (537.4211 ± 5 ppm, upper panel) and [2H6]25-D3 (543.4588 ± 5 ppm, 
lower panel); (B) 3βH-Δ5-BA (511.3691 ± 5 ppm); (C) 3β,7β-diH-Δ5-BA and 3α,7α-diH-Δ5-BA + 7αH,3O-
Δ4-BA (527.3640 ± 5 ppm, upper panel); 7αH,3O-Δ4-BA (522.3326 ± 5 ppm, lower panel,); (D) 3β-HCA 
+ 3O-CA (553.4161 ± 5 ppm, upper panel,); 3O-CA (548.3847 ± 5 ppm, lower panel); (E - H) 3β,7α,24-
triHCA + 7α,24-diH,3O-CA, 3β,7α,25-triHCA + 7α,25-diH,3O-CA and 3β,7α,12α-triHCA + 7α,12α-
diH,3O-CA  (585.4059 ± 5 ppm, upper panels); (E) Lower panel, 7α,24-diH,3O-CA, 7α,25-diH,3O-CA and 
7α,12α-diH,3O-CA (580.3739 ± 5 ppm); (F – H) Lower panels show MRM chromatograms targeting (F) 
3β,7α,24-triHCA + 7α,24-diH,3O-CA; (G) 3β,7α,25-triHCA + 7α,25-diH,3O-CA; (H) 3β,7α,12α-triHCA 
and 7α,12α-diH,3O-CA. Authentic standards are not available for 3β,7α,12α-triHCA and 7α,12α-
diH,3O-CA. Coloured dashed lines indicate the coincidence of oxysterols between chromatograms. 
MS3 spectra are presented in Figures S11 & S12. 
Figure S11. MS3 fragmentation of GP-derivatised 25-hydroxyvitamin D3 and sterol acids in plasma. MS3 
([M]+→[M-Py-H2O]+→) spectra of (A) 25-D3 and (B) [2H6]25-D3. MS3 ([M]+→[M-Py]+→) spectra of (C) 
3βH-Δ5-BA; (D) 3β,7β-diH-Δ5-BA; (E) 3β,7α-diH-Δ5-BA + 7αH,3O-Δ4-BA; (F) 7αH,3O-Δ4-BA; (G) 3β-HCA 
+ 3O-CA; (H) 3O-CA. The formation of key fragment ions is illustrated in Figure S4M-O. 
Figure S12. MS3 fragmentation of GP-derivatised of trihydroxycholestenoic (triHCA) and dihydroxy-3-
oxocholestenoic acids (diH,3O-CA) in plasma. MS3 ([M]+→[M-Py]+→) spectra of (A) 3β,7α,24-triHCA + 
7α,24-diH,3O-CA; (B) 3β,7α,25-triHCA + 7α,25-diH,3O-CA; (C) 3β,7α,12α-triHCA + 7α,12α-diH,3O-CA 
(no authentic standard). The formation of key fragment ions is illustrated in Figure S4P-R.  
Figure S13. MS3 fragmentation of GP-derivatised oxysterols in plasma. MS3 spectra of the postulated 
structures (A) 3β,25-diHCA or 3β,25,x-trihydroxycholest-5-en-y-one (no authentic standards available); 
(B) 3β,27-diHCA or 3β,27,x-trihydroxycholest-5-en-y-one (no authentic standards available); (C) 3β,x-
diHCA or 3β,x,y-trihydroxycholest-5-en-z-one (no authentic standards available); (D) 3β,22,25-
trihydroxycholest-5-en-24-one or 3β,x-diHCA (no authentic standard); (E) 3β,22-dihydroxycholest-5-
en-24-one or 3β,20-dihydroxycholest-5-en-22-one (no authentic standard); (F) 7α,x-diH,3O-CA (no 
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authentic standard). The more likely structures are given in italics. The formation of key fragment ions 
is illustrated in Figure S4S-V. 
Figure S14. MS3 fragmentation of GP-derivatised of trihydroxycholestenoic (triHCA) and dihydroxy-3-
oxocholestenoic acids (diH,3O-CA) in CSF. MS3 ([M]+→[M-Py]+→) spectra of (A) 3β,7α,24-triHCA + 
7α,24-diH,3O-CA; (B) 3β,7α,25-triHCA + 7α,25-diH,3O-CA; (C) 3β,7α,12α-triHCA + 7α,12α-diH,3O-CA 
(no authentic standard) and (D) 3β,7α,x-triHCA + 7α,x-diH,3O-CA. The formation of key fragment ions 
is illustrated in Figure S4P-R. 
Table S1. Systematic and common names of sterols including oxysterols and sterol-acids identified or 
partially identified in the current study. Supplier of reference standards are indicated when available. 
Table S2. Figures of merits when varying amount of OxysterolSPLASH at a plasma volume of 100 µL. 
Table S3. Figures of merit revealed by standards additions to (A) 100 µL of plasma using 50 µL of 
OxysterolSPLASH and (B) 100 µL CSF using 100 µL of OxysterolSPLASH. 











































Schematic illustration of sample preparation. Single-phase 
liquid extraction is performed into ethanol containing 









100 μL Plasma  + 1 to 5 
levels of standard additions









SPLASH 50 μL 







100 μL CSF + 1 to 5 levels of 
standard additions










Individual IS in 
EtOH
SPLASH 20 μL 
0.35M KOH in 
EtOH











SPLASH 20 μL in 
EtOH
Varying Amounts 
of CSF or SPLASH 
1-Phase Extraction
200 – 50 μL CSF
SPLASH 10 - 20 
μL in EtOH

Record high resolution accurate mass spectra via LC-MS
Generate RICs for potential oxysterols, cholestenoic and 
cholenoic acids
Record MS3 spectra on candidate sterols
Postulate structures from retention time data, accurate mass 
measurement and MS3 spectra
Identify structures where possible against reference 
standards or library thereof 
Where standards not available postulate structures to reveal 
a “presumptive” identification  
Perform absolute quantification, where possible, on 
identified structures against exact isotope labelled surrogates
If absolute quantification not possible perform semi-
quantification against isotope labelled structural analogue
In the absence of authentic standard perform approximate 
quantification against isotope labelled structural analogue  
Flowchart 3




100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)










































1B=GPd0_s2_03#3073  RT: 14.89  






1B=GPd0_s2_03#3589  RT: 17.40  






1B=GPd0_s2_03#3601  RT: 17.46  












100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.02





























































10.030.90 6.861.47 5.67 12.22 12.887.472.47 4.733.47 13.95 15.07 16.57
NL: 2.34E4
TIC F: ITMS + c ESI Full ms3 
534.41@cid30.00 455.36@cid35.00 





TIC F: ITMS + c ESI Full ms3 
541.45@cid30.00 462.41@cid35.00 













100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3123 RT: 15.14 AV: 1 NL: 3.85E3
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]












































189.2 273.3 310.4177.3 412.5 438.3253.2 284.3205.4 369.5216.2 233.3135.3 339.4
S3A
MS3: 539455
15.14 min (37 min gradient)
24S-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3903 RT: 18.89 AV: 1 NL: 1.19E2
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]

















































18.89 min (37 min gradient)
24R-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3080 RT: 14.92 AV: 1 NL: 1.24E4
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]













































164.1 381.4 419.5137.1 273.2 299.3231.1203.3 239.2 320.3 339.2 447.4179.2
S3C
MS3: 546462
14.92 min (37 min gradient)
[2H7]24S-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3866 RT: 18.71 AV: 1 NL: 4.78E3
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]













































325.3 381.2367.3164.0 419.5231.1203.2137.0 310.2273.3 283.3 327.4 445.4243.2184.1 462.2
S3D
MS3: 546462
18.71 min (37 min gradient)
[2H7]24R-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3285 RT: 15.94 AV: 1 NL: 2.08E3
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]









































381.4 427.4325.2177.2 294.4163.1 242.1 311.3151.1 372.4350.3 394.6255.1 283.3133.3 185.3
S3E
MS3: 539455
15.94 min (37 min gradient)
25-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3256 RT: 15.79 AV: 1 NL: 1.12E4
F: ITMS + c ESI Full ms3 545.47@cid30.00 461.40@cid35.00 [125.00-555.00]









































381.4325.2163.1 311.3 400.4151.1 283.2 353.3130.8 171.2 444.6273.1 415.9259.3202.2 232.3223.2
S3F
MS3: 545461
15.79 min (37 min gradient)
[2H6]25-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3663 RT: 17.75 AV: 1 NL: 4.63E3
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]













































177.1 394.4380.5 438.2135.1 203.1 211.0 245.1 255.2 271.2 299.2 365.2313.2 331.4
S3G
MS3: 539455
17.75 min (37 min gradient)
(25R)26-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3628 RT: 17.58 AV: 1 NL: 2.24E4
F: ITMS + c ESI Full ms3 545.47@cid30.00 461.40@cid35.00 [125.00-555.00]











































389.5177.2 327.3137.0 299.1 400.5189.3 217.2 386.4371.4 444.3231.2 255.2 271.1 353.3335.4 459.4
S3H
MS3: 545461
17.58 min (37 min gradient)
[2H6](25R)26-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #1658 RT: 7.86 AV: 1 NL: 1.28E3
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]












































445.0325.4 372.5273.3231.1 339.4191.2147.1 402.3201.2 283.2 320.6264.3 306.4177.2 223.2 236.3 420.6368.4 389.6
S3I
MS3: 546462
7.86 min (37 min gradient)
[2H7]22R-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #1762 RT: 8.35 AV: 1 NL: 4.92E1
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]




















































8.35 min (17 min gradient)
22S-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #1760 RT: 8.34 AV: 1 NL: 1.04E5
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]















































231.2 399.5177.1 253.2 282.2 339.3 445.6299.3 312.3 417.5145.1 186.2 203.1 357.3 402.2
S3K
MS3: 546462
8.34 min (17 min gradient)
[2H7]22S-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_03 #3790 RT: 18.35 AV: 1 NL: 6.81E3
F: ITMS + c ESI Full ms3 545.47@cid30.00 461.40@cid35.00 [125.00-555.00]












































327.3177.2 402.4137.0 188.1 233.3 371.4271.1253.2217.1 285.2 311.3 353.3 444.2
MS3: 545461

























100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #1936 RT: 9.13 AV: 1 NL: 5.83E2
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]











































163.2 231.2199.2 271.1 364.9325.4133.1 261.4 382.5308.2285.3 400.5213.4
S5A
MS3: 539455
9.13 min (17 min gradient)
7β-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #1928 RT: 9.10 AV: 1 NL: 1.77E3
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]












































188.1 445.2163.1 404.3237.1199.1146.9 346.4290.1227.3 280.1 355.3332.3254.2 308.3 388.4 420.3 462.8
S5B
MS3: 546462
9.13 min (17 min gradient)
[2H7]7β-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #2062 RT: 9.70 AV: 1 NL: 1.19E4
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]











































179.1 233.3 383.3 410.4
157.1 325.3188.2 203.2 363.5299.3281.3225.2 253.2137.0 339.4 438.8422.4
S5C
MS3: 539455
9.70 min (17 min gradient)
7α-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #2054 RT: 9.66 AV: 1 NL: 2.06E4
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]











































332.3158.8 294.3188.1 280.3226.1 240.2 387.4360.4306.5 445.4149.0 429.4254.3211.1
S5D
MS3: 546462
9.66 min (17 min gradient)
[2H7]7α-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #2128 RT: 9.97 AV: 1 NL: 1.11E3
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]















































9.97 min (17 min gradient)
6β-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #2120 RT: 9.93 AV: 1 NL: 2.25E3
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]












































362.5175.2 445.5185.2 387.5147.0 229.0200.2 332.5280.4269.2252.3 347.4318.4292.2135.1 460.6
S5F
MS3: 546462
9.93 min (17 min gradient)
[2H7]6β-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #1989 RT: 9.37 AV: 1 NL: 1.07E3
F: ITMS + c ESI Full ms3 534.41@cid30.00 455.36@cid35.00 [125.00-550.00]















































314.4285.3 329.4199.1 253.3 381.3225.2157.1 343.2173.1 266.2 325.3234.3 301.3197.0 438.3142.0
S5G
MS3: 534455
9.37 min (17 min gradient)
7-OC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #1979 RT: 9.33 AV: 1 NL: 2.41E3
F: ITMS + c ESI Full ms3 541.45@cid30.00 462.41@cid35.00 [125.00-555.00]














































385.4253.2226.1145.1 159.2 173.1 343.1214.1 270.3 290.3 321.3 445.1185.1 310.4143.0
S5H
MS3: 541462
9.33 min (17 min gradient)
[2H7]7-OC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #2061 RT: 9.69 AV: 1 NL: 9.01E3
F: ITMS + c ESI Full ms3 534.41@cid30.00 455.36@cid35.00 [125.00-550.00]













































412.2233.2 325.4175.1 188.2 203.1 247.2217.1 363.3313.2 380.4134.2 268.0 297.4 438.8343.3
S5I
MS3: 534455
9.69 min (17 min gradient)
7α-HCO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #2051 RT: 9.65 AV: 1 NL: 6.05E3
F: ITMS + c ESI Full ms3 541.45@cid30.00 462.41@cid35.00 [125.00-555.00]













































390.5 417.4233.1 294.3163.1 332.4213.2145.1 203.2 253.2 370.3282.4 348.4 374.5318.4 447.5 462.2
S5J
MS3: 541462
9.65 min (17 min gradient)
[2H7]7α-HCO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_02 #1792 RT: 8.48 AV: 1 NL: 5.96E1
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]





















































8.48 min (17 min gradient)
12α-HC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 37.01










































31.619.10 12.52 31.0212.074.50 32.2220.834.45










m/z= 555.4289-555.4345 F: FTMS + 





m/z= 561.4666-561.4722 F: FTMS + 

















100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 37.01

































9.07 9.12 20.88 31.9812.64 21.529.302.20 30.7224.36 29.814.42 20.6713.91 16.77
NL: 2.77E4
m/z= 550.3975-550.4031 F: FTMS + 




RT: 0.00 - 17.00


































m/z= 550.3975-550.4031 F: FTMS + 













100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 37.01















































9.024.392.45 16.161.79 16.83 31.0519.8715.8412.34
NL: 2.51E5
m/z= 564.3768-564.3824 F: FTMS + 





m/z= 567.3956-567.4012 F: FTMS + 











100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 37.01



















































1.79 32.293.09 8.85 10.65 32.7022.8520.6714.44
NL: 3.58E5
m/z= 569.4082-569.4138 F: FTMS + 





m/z= 572.4269-572.4327 F: FTMS + 













100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1072 RT: 5.03 AV: 1 NL: 2.77E3
F: ITMS + c ESI Full ms3 555.43@cid30.00 471.36@cid35.00 [125.00-560.00]









































381.4280.3 323.1 408.5199.3 231.2 260.2191.9163.1151.0 223.2 296.2251.3 363.3337.8
S7A
MS3: 555471
5.03 min (17 min gradient)
7α,25-diHC + 7α,25-diHCO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1059 RT: 4.97 AV: 1 NL: 1.29E3
F: ITMS + c ESI Full ms3 561.47@cid30.00 477.40@cid35.00 [130.00-570.00]










































431.5398.4313.3 460.5417.5151.1 260.3 323.2 368.4 387.3297.3137.0 165.2 271.3203.3184.2 245.3232.3
S7B
MS3: 561477
4.97 min (17 min gradient)
[2H6]7α,25-diHC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1156 RT: 5.43 AV: 1 NL: 5.27E2
F: ITMS + c ESI Full ms3 555.43@cid30.00 471.36@cid35.00 [125.00-560.00]










































151.1 381.6231.3 411.2277.2 303.5255.2174.1 395.6353.3195.2
S7C
MS3: 555471
5.43 min (17 min gradient)
7α,(25S)26-diHC + 7α,(25S)26-diHCO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1147 RT: 5.39 AV: 1 NL: 3.99E2
F: ITMS + c ESI Full ms3 561.47@cid30.00 477.40@cid35.00 [130.00-570.00]












































417.2186.1 405.5321.4 441.4386.4309.3 460.3251.4 363.6 431.4141.2 176.1159.1 295.2199.2 227.3 343.5
S7D
MS3: 561477
5.39 min (17 min gradient)
[2H6]7α,(25S)26-diHC
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1204 RT: 5.64 AV: 1 NL: 3.64E3
F: ITMS + c ESI Full ms3 555.43@cid30.00 471.36@cid35.00 [125.00-560.00]












































454.0179.1 233.2201.1163.1 281.1223.1 325.3145.0 251.2 341.2299.3 367.2
S7E
MS3: 555471
5.64 min (17 min gradient)
7α,(25R)26-diHC + 7α,(25R)26-diHCO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1191 RT: 5.59 AV: 1 NL: 4.27E2
F: ITMS + c ESI Full ms3 561.47@cid30.00 477.40@cid35.00 [130.00-570.00]











































185.0 310.2277.3266.3227.1 460.0399.3233.4157.2 362.3209.2 285.0149.0 319.3 372.4348.4
S7F
MS3: 561477
5.59 min (17 min gradient) 
[2H6]7α,(25R)26-diHC
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1078 RT: 5.06 AV: 1 NL: 2.88E3
F: ITMS + c ESI Full ms3 550.40@cid30.00 471.36@cid35.00 [125.00-560.00]









































454.4323.3231.3215.1 381.4 407.4351.5151.2 252.4190.2 280.0173.2 369.2309.3
S7G
MS3: 550471
5.06 min (17 min gradient)
7α,25-diHCO
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1202 RT: 5.63 AV: 1 NL: 3.56E3
F: ITMS + c ESI Full ms3 550.40@cid30.00 471.36@cid35.00 [125.00-560.00]












































399.3179.1 454.2381.4188.2 229.2163.1 297.2253.3 413.5341.3243.1 325.3209.2 265.5 367.3144.1 282.2
S7H
MS3: 550471
5.63 min (17 min gradient)
7α,(25R)26-diHCO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_04 #1812 RT: 8.41 AV: 1 NL: 2.53E2
F: ITMS + c ESI Full ms3 555.43@cid30.00 471.36@cid35.00 [125.00-560.00]












































195.2186.3 321.5252.0 295.2 379.4 407.5338.3280.3150.1 175.5 357.5225.1 245.3161.3 266.3
S7I
MS3: 555471
8.41 min (17 min gradient)
7α,12α-diHC + 7α,12α-diHCO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #703 RT: 3.29 AV: 1 NL: 1.23E3
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]












































406.4163.1 395.4 468.2179.2 317.4 349.4341.2309.3 377.6254.2 278.2215.1 223.3195.1145.1 470.3
S8A
MS3: 569485
3.29 min (17 min gradient)
3β,7β-diHCA(25R)
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #1083 RT: 5.13 AV: 1 NL: 7.92E3
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]












































231.2 378.3 395.3 406.4
179.1 188.2 233.2163.2 468.5323.3225.1 251.1145.2 355.3277.4 339.2297.3
S8B
MS3: 569485
5.13 min (17 min gradient)
3β,7α-diHCA(25S) + 7αH,3O-CA(25S)
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #1080 RT: 5.11 AV: 1 NL: 9.87E3
F: ITMS + c ESI Full ms3 572.43@cid30.00 488.36@cid35.00 [130.00-580.00]












































231.1 416.3381.3 398.3203.1179.1 266.2161.1 211.1 253.2 323.3 358.4280.3 306.3 339.3146.0 471.6
S8C
MS3: 572488
5.11 min (17 min gradient)
[2H3]3β,7α-diHCA(25S)
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #1133 RT: 5.36 AV: 1 NL: 3.45E4
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]












































231.1 395.3378.3 406.3179.1 188.1 203.1 323.2253.2 277.2171.1145.1 351.3289.2 376.4 468.5
S8D
MS3: 569485
5.36 min (17 min gradient)
3β,7α-diHCA(25R) + 7αH,3O-CA(25R)
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #1120 RT: 5.30 AV: 1 NL: 1.20E4
F: ITMS + c ESI Full ms3 572.43@cid30.00 488.36@cid35.00 [130.00-580.00]













































416.4398.4231.2 381.4179.1 471.2323.3203.2 253.3 266.3163.2 358.4332.4280.3230.5 311.3147.2
S8E
MS3: 572488
5.30 min (17 min gradient)
[2H3]3β,7α-diHCA(25R)
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #1082 RT: 5.12 AV: 1 NL: 4.86E3
F: ITMS + c ESI Full ms3 564.38@cid30.00 485.34@cid35.00 [130.00-575.00]












































378.4179.2 317.2203.2 223.2 277.3 351.3 468.5171.2 253.2 329.3145.1 309.2
S8F
MS3: 564485
5.12 min (17 min gradient)
7αH,3O-CA(25S)
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #1132 RT: 5.35 AV: 1 NL: 2.29E4
F: ITMS + c ESI Full ms3 564.38@cid30.00 485.34@cid35.00 [130.00-575.00]















































233.2 393.4317.2188.2 223.1 377.3355.2171.1 281.2 325.3251.2 297.3145.1
S8G
MS3: 564485
5.35 min (17 min gradient)
7αH,3O-CA(25R)
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #1119 RT: 5.30 AV: 1 NL: 1.21E4
F: ITMS + c ESI Full ms3 567.40@cid30.00 488.36@cid35.00 [130.00-580.00]













































188.2 280.2 323.3238.2 253.2226.2157.1 308.3 358.3332.2144.2 471.9
S8H
MS3: 567488




100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d7 (cert)
RT: 0.00 - 17.02




































11.49 12.36 13.68 14.68 16.24
10.96






m/z= 523.4393-523.4445 F: FTMS + p 







m/z= 530.4831-530.4885 F: FTMS + p 







m/z= 521.4236-521.4288 F: FTMS + p 














100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d7 (cert)
EY_200610_[190628_NIST-QC_OxySplash_+22S-HCO-d7_+Chol-d7_Fr3A=GPd5_Fr3B=GPd0_1in100_s3]_01 #2379 RT: 11.01 AV: 1 NL: 2.73E6
F: ITMS + c ESI Full ms3 523.44@cid30.00 439.37@cid35.00 [120.00-530.00]












































327.3137.0 205.1 313.3245.2 255.3 382.5231.2 285.3191.1 365.4 424.5339.4
MS3: 523439




100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d7 (cert)
EY_200610_[190628_NIST-QC_OxySplash_+22S-HCO-d7_+Chol-d7_Fr3A=GPd5_Fr3B=GPd0_1in100_s3]_01 #2368 RT: 10.97 AV: 1 NL: 1.37E6
F: ITMS + c ESI Full ms3 530.49@cid30.00 446.41@cid35.00 [120.00-535.00]













































137.0 327.2 419.1203.2 213.2 245.2 389.4255.2 299.3185.2 273.2 372.6330.4 431.5347.5
MS3: 530446




100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d7 (cert)
EY_200610_[190628_NIST-QC_OxySplash_+22S-HCO-d7_+Chol-d7_Fr3A=GPd5_Fr3B=GPd0_1in100_s3]_02 #2232 RT: 10.36 AV: 1 NL: 1.14E3
F: ITMS + c ESI Full ms3 521.43@cid30.00 437.35@cid35.00 [120.00-530.00]












































259.3 395.2203.1 299.3 325.4137.0 245.4 285.2231.2185.2 205.2 265.2 341.3 410.4
MS3: 521437




100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d7 (cert)
EY_200610_[190628_NIST-QC_OxySplash_+22S-HCO-d7_+Chol-d7_Fr3A=GPd5_Fr3B=GPd0_1in100_s3]_02 #2328 RT: 10.76 AV: 1 NL: 2.80E3
F: ITMS + c ESI Full ms3 521.43@cid30.00 437.35@cid35.00 [120.00-530.00]











































229.2 366.4137.0 191.1163.0 203.1 299.4 363.3282.3233.1 337.5311.3269.4 419.3
MS3: 521437






100uL NIST (2018) + 2017-Protocol-iSTDs (20ng 24RS-HC-d6-cert) + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.01

















































m/z= 537.4185-537.4239 F: FTMS + p 






m/z= 543.4561-543.4615 F: FTMS + p 











100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.01













































m/z= 511.3665-511.3717 F: FTMS + 








100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.00
















































9.33 12.903.231.50 13.147.853.30 5.15 15.36 16.440.14
NL: 4.95E4
m/z= 527.3614-527.3666 F: FTMS + 





m/z= 522.3300-522.3352 F: FTMS + 













100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.00


















































14.056.91 9.09 12.11 14.148.59 9.69
13.943.55 5.223.30 9.75 12.633.602.29 7.90 14.286.531.51 6.443.25 3.91 5.05
NL: 8.56E5
m/z= 553.4133-553.4189 F: FTMS + 





m/z= 548.3820-548.3874 F: FTMS + 











100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.00






















































m/z= 585.4030-585.4088 F: FTMS + 





m/z= 580.3716-580.3774 F: FTMS + 














100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.00




















































11.269.952.97 5.99 9.683.10 5.41
6.29 7.32 12.03 14.2513.263.74
NL: 1.24E4
m/z= 585.4030-585.4088 F: FTMS + p ESI 





m/z= 427.0000-427.7000 F: ITMS + c ESI Full 
ms3 585.41@cid30.00 501.33@cid35.00 











100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.00

























































8.36 10.195.19 10.76 11.77 13.21 15.34
NL: 1.24E4
m/z= 585.4030-585.4088 F: FTMS + p ESI 





m/z= 455.0000-455.7000 F: ITMS + c ESI Full 
ms3 585.41@cid30.00 501.33@cid35.00 











100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
RT: 0.00 - 17.00






















































3.181.60 5.555.15 7.43 13.988.680.94 12.369.17
NL: 1.24E4
m/z= 585.4030-585.4088 F: FTMS + p ESI 





m/z= 422.0000-422.7000 F: ITMS + c ESI Full 
ms3 585.41@cid30.00 501.33@cid35.00 










100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_09 #1737 RT: 8.19 AV: 1 NL: 4.20E3
F: ITMS + c ESI Full ms3 537.42@cid30.00 435.34@cid35.00 [115.00-545.00]













































390.3149.2 325.3161.2 213.2 280.5 353.3297.4143.1 257.2200.2 229.0 408.5
11A
MS3: 537435
8.19 min (17 min gradient)
25-D3
EY_191014_100uL-NIST-QC_with_2017-Pro... 10/16/19 13:46:25
100uL NIST (2018) + 2017-Protocol-iSTDs (20ng 24RS-HC-d6-cert) + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_with_2017-Protocol-iSTDs_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s7_09 #1750 RT: 8.19 AV: 1 NL: 1.28E4
F: ITMS + c ESI Full ms3 543.46@cid30.00 441.37@cid35.00 [120.00-550.00]















































367.4323.2310.3281.3 382.4225.2 243.3 263.2 351.4 423.3
11B
MS3: 543441
8.19 min (17 min gradient)
[2H6]25-D3
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 05:51:45
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_11 #703 RT: 3.35 AV: 1 NL: 6.55E2
F: ITMS + c ESI Full ms3 511.37@cid30.00 427.30@cid35.00 [115.00-515.00]













































355.3171.3143.1 410.2245.3203.3 214.2 314.3253.0 346.2175.0 271.2135.0 302.3
11C
MS3: 511427
3.35 min (17 min gradient)
3βH-Δ5-BA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:07:57
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_06 #238 RT: 1.12 AV: 1 NL: 1.08E3
F: ITMS + c ESI Full ms3 527.36@cid30.00 443.29@cid35.00 [120.00-535.00]











































353.2 371.3179.1 275.2235.1163.2133.1 327.2219.0202.0 257.2 295.3 368.3335.3 426.2313.3
11D
MS3: 527443
1.12 min (17 min gradient)
3β,7β-diH-Δ5-BA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:07:57
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_06 #348 RT: 1.62 AV: 1 NL: 3.59E3
F: ITMS + c ESI Full ms3 527.36@cid30.00 443.29@cid35.00 [120.00-535.00]














































231.2 263.3188.2153.1 335.3217.2 275.3251.2 370.5 426.4313.5133.2 301.4
11E
MS3: 527443
1.62 min (17 min gradient)
3β,7α-diH-Δ5-BA + 7αH,3O-Δ4-BA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:07:57
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_06 #352 RT: 1.64 AV: 1 NL: 2.12E3
F: ITMS + c ESI Full ms3 522.33@cid30.00 443.29@cid35.00 [120.00-535.00]













































353.4 426.1179.1171.2 188.2 261.5 324.3311.3 335.5207.2 231.3 243.4147.3 287.2 428.3
11F
MS3: 522443
1.64 min (17 min gradient)
7αH,3O-Δ4-BA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:28:42
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_07 #1524 RT: 7.22 AV: 1 NL: 3.11E4
F: ITMS + c ESI Full ms3 553.42@cid30.00 469.34@cid35.00 [125.00-560.00]














































137.1 378.3233.2205.1 253.2 353.1271.2 412.5310.2299.3 339.2 452.8
11G
MS3: 553469
7.22 min (17 min gradient)
3β-HCA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:28:42
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_07 #1532 RT: 7.26 AV: 1 NL: 4.64E2
F: ITMS + c ESI Full ms3 548.38@cid30.00 469.34@cid35.00 [125.00-560.00]















































231.2 452.3287.3 327.3269.1145.3 312.2186.5 378.4355.3
11H
MS3: 548469
7.26 min (17 min gradient)
3O-CA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:28:42
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_07 #327-340 RT: 1.56-1.60 AV: 3 NL: 5.27E1
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]















































151.2 191.2 376.3317.4179.1 225.1 339.0 484.1307.9279.2
S12A
MS3: 585501
1.58 min (17 min gradient)
3β,7α,24-triHCA + 7α,24S-diH,3O-CA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:28:42
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_07 #558-588 RT: 2.64-2.76 AV: 6 NL: 7.96E1
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]











































394.6 465.3413.4225.2 282.2211.2 349.3 422.3198.2 321.3298.5249.1 484.0155.3 379.4 404.2179.0 231.1 281.4 365.5144.9
S12B
MS3: 585501
2.72 min (17 min gradient)
3β,7α,25-triHCA + 7α,25-diH,3O-CA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:28:42
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_07 #715 RT: 3.37 AV: 1 NL: 5.89E2
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]













































392.2223.2 267.2 303.4 419.3249.2193.1179.0
376.2341.2281.1218.3 305.3158.2 265.2 402.3141.1 484.3333.2
12C
MS3: 585501
3.37 min (17 min gradient)
3β,7α,12α-triHCA + 7α,12α-diH,3O-CA
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #413 RT: 1.93 AV: 1 NL: 1.39E4
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]








































325.1417163.1502 353.3025 399.2568282.2573227.2487 253.1932188.1540
S13A
MS3: 569485
1.93 min (17 min gradient)
3β,25-diHCA or 3β,25,x-triHC-yO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #528 RT: 2.47 AV: 1 NL: 5.48E2
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]




















































2.47 min (17 min gradient)
3β,27-diHCA or 3β,27,x-triHC-yO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #843 RT: 3.97 AV: 1 NL: 1.70E2
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]














































337.4 392.5 409.3271.1149.2 254.8197.2 381.1325.2 349.2245.0 468.1215.2 301.3
S13C
MS3: 569485
3.97 min (17 min gradient)
3β,x-diHCA or 3β,x,y-triHC-zO
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_05 #948 RT: 4.48 AV: 1 NL: 6.92E3
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]










































367.3 439.4325.3163.1151.1 342.2 413.5393.4297.3214.1 355.2 380.4253.2 265.1171.2 229.1199.3 470.2
S13D
MS3: 569485
4.48 min (17 min gradient)
3β,x-diHCA or 3β,22,25-triHC-24O
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:28:42
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_07 #1454 RT: 6.90 AV: 1 NL: 4.69E3
F: ITMS + c ESI Full ms3 553.42@cid30.00 469.34@cid35.00 [125.00-560.00]












































297.4 351.3311.3253.2231.2 283.2 378.4 451.4326.3177.1 397.3203.1 271.4137.1 454.3433.6
S13E
MS3: 553469
6.90 min (17 min gradient)
3β,22-diHC-24O or 3β,20-diHC-22O
EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:28:42
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug Chol-D7(certified)
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0_s2_07 #435 RT: 2.04 AV: 1 NL: 5.27E2
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]














































411.8269.3233.2150.9 364.3258.1 374.3286.2178.9 211.1 332.9 341.2315.3201.2 408.2157.4
S13F
MS3: 585501
2.04 min (17 min gradient)
3β,7α,x-triHCA + 7α,x-diH,3O-CA
EY_191029_100uL-Cambridge-CSF-pool_20... 10/29/19 21:38:19
100uL Cambridge Pooled CSF (2019) + 20ul OxysterolSPLASH + 1ng 22S-HCO-D7 + 0.2ug Chol-D7(certified)
EY_191029_100uL-Cambridge-CSF-pool_20uL-OxySPLASH_r2_NON-HYDRO_+1ng-22S-HCO-d7_Fr1A=GPd5_Fr1B=GPd0_s2_neat_07 #425 RT: 1.87 AV: 1 NL: 3.01E2
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]















































335.5 366.3 400.4151.1 253.3160.1 233.2 378.5307.4287.2 465.5348.5266.2147.1 243.8229.1
MS3: 585501




100uL Cambridge Pooled CSF (2019) + 20ul OxysterolSPLASH + 1ng 22S-HCO-D7 + 0.2ug Chol-D7(certified)
EY_191029_100uL-Cambridge-CSF-pool_20uL-OxySPLASH_r2_NON-HYDRO_+1ng-22S-HCO-d7_Fr1A=GPd5_Fr1B=GPd0_s2_neat_07 #700 RT: 3.11 AV: 1 NL: 1.34E3
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]

















































100uL Cambridge Pooled CSF (2019) + 20ul OxysterolSPLASH + 1ng 22S-HCO-D7 + 0.2ug Chol-D7(certified)
EY_191029_100uL-Cambridge-CSF-pool_20uL-OxySPLASH_r2_NON-HYDRO_+1ng-22S-HCO-d7_Fr1A=GPd5_Fr1B=GPd0_s2_neat_07 #845 RT: 3.76 AV: 1 NL: 2.89E2
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]












































279.2 411.3 447.4351.3199.0 209.2151.1 365.3
315.4174.5 406.3235.2
281.3 390.3198.0 264.2245.2 322.2218.3 305.3 350.4149.2
MS3: 585501




100uL Cambridge Pooled CSF (2019) + 20ul OxysterolSPLASH + 1ng 22S-HCO-D7 + 0.2ug Chol-D7(certified)
EY_191029_100uL-Cambridge-CSF-pool_20uL-OxySPLASH_r2_NON-HYDRO_+1ng-22S-HCO-d7_Fr1A=GPd5_Fr1B=GPd0_s2_neat_07 #540 RT: 2.39 AV: 1 NL: 3.45E3
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]












































179.0 392.5239.2231.1 378.5215.1 333.3 484.3349.4171.0 253.0 279.3 293.3 305.4146.1
MS3: 585501
2.39 min (17 min gradient)
3β,7α,x-triHCA + 7α,x-diH,3O-CA
S14D
